Protocol I8F-MC-GPIF (c) 
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in 
Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, 
Placebo-Controlled Trial (SURMOUNT-OSA) 
[STUDY_ID_REMOVED]    
Approval Date: 02-JUN-2023
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of tirzepatide (LY3298176) , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsidiaries.  
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercial ly confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Master Protocol Title:  A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide 
Once Weekly in Participants who ha ve Obstructive Sleep Apnea  and Obesity: A 
Randomized, Double -Blind, Placebo -Controlled Trial (SURMOUNT -OSA)
Protocol Number:  I8F-MC-GPIF  
Amendment Number: c 
List of Intervention -Specific Appendices (ISAs):  
I8F-MC-GPI1 : Participants with OSA  unwilling or unable to use  PAP therapy  
I8F-MC-GPI2 : Participants with OSA on PAP  therapy  
Compound : Tirzepatide (LY3298176)  
Brief Title:  A Master Protocol for Tirzepatide in  Participants with  Obstructive Sleep Apnea and 
Obesity  
Study Phase:  3 
Acronym : SURMOUNT -OSA  
Sponsor Name: Eli Lilly and Company  
Legal Registered Address: Indianapolis, Indiana , USA 46285  
Regulatory Agency Identifier Number : 
IND: 157090  
Approval Date:  Protocol  Amendment ( c) Electronically  Signed and  Approved  by Lilly  on date 
provided below.  
Document ID:  VV-CLIN -116270  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
2 Medical Monitor Name and Contact Information will be provided separately . 
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
3 Protocol Amendment Summary of Changes Table   
 
DOCUMENT HISTORY  
Document  Date  
Amendment b  30-Sep-2022  
Amendment a  10-Feb-2022  
Original Protocol  27-Jan-2022  
Amendment [c] 
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
This amendment includes changes made to the primary and key secondary endpoints  for change 
in AHI and clarification around timing of the PHQ -9 assessment.  Revisions were made to clarify 
the role of central reading of  PSG scores.  
 
Protocol changes have been made as outlined in the following table.  
 
Section # and Name  Description of Change  Brief Rationale  
1.1. Synopsis  
and  
3. Objectives, Endpoints, and 
Estimands  
 Primary Objective:  
Removed “percent”  To align with change made 
to primary endpoint . Note, 
the current sample size is 
deemed adequate for the 
assessment  of the updated 
primary endpoint and all key 
secondary endpoints  
Primary Endpoints:  
Updated primary endpoint from 
“Percent change in AHI from 
baseline to Week 52” to 
“Change in AHI from baseline 
to Week 52  (events per hour) ” In response to regulatory 
recommendation  
Key Secondary Endpoints : 
Updated first endpoint from 
“Change in AHI” to “ Percent 
change in AHI ” Changed to reflect revisions 
in endpoint hierarchy   
1.3. Schedule of Activities  
(SoA)  
 “PHQ -9” row:  
Added additional information to 
Comments:  “PHQ -9 at V7 and 
V11 may be scheduled for any 
day +/ - 14 days. ” Clarification  
5.2 Exclusion Criteria  EC#44: Added glucose -lowering 
medication, including metformin  Clarification  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
4 Section # and Name  Description of Change  Brief Rationale  
to the list of  medications  
prohibited within 3 months of 
Visit 1  
6.8.2 Prohi bited Concomitant 
Medications  Added glucose -lowering 
medication, including metformin 
to the list of prohibited 
concomitant medications  Clarification  
8.1.1.1 Polysomnography  Added text, “ The eligibility 
criteria and AHI related 
endpoints of the study will be 
assessed based on central 
reading of the PSG. ” Clarification that PSG based  
endpoints are based on result 
determined from central 
reading of PSG  
9.1 Statistical Hypotheses  “Percent” has been removed  
from the description of the 
treatment effect definit ion To align with changes made 
in Section 1.1 and Section 3  
9.3.1 General Considerations  A statement was added to clarify 
that efficacy analyses  will be 
conducted on all participants 
meeting study eligibility criteria  Clarifications added to 
ensure consistency of text in 
Section 9.3.1  with the table 
in Section 9.2   
The first intercurrent event has 
been updated to include 
incorrect study procedures 
leading to invalid measurements  Clarifying how invalid 
measurements will be 
handled in the analysis.  
9.3.2 Primary Analysis  “Percent” has been removed 
when describing the primary 
endpoint  To align with changes made 
in Section 1.1 and Section 3  
9.3.3 Analysis of Key 
Secondary Endpoints  “Percent” has been added when 
descri bing the analysis  To align with c hanges made 
in Section 1.1 and Section 3  
Throughout  Editorial corrections  Minor, therefore not 
described  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
5 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ .......... 9 
1.1. Synopsis  ................................ ................................ ................................ ............................ 9 
1.2. Schema  ................................ ................................ ................................ ............................ 12 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 14 
2. Introduction  ................................ ................................ ................................ ................... 24 
2.1. Study Rationale  ................................ ................................ ................................ ............... 24 
2.2. Background  ................................ ................................ ................................ ..................... 24 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 25 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......26 
4. Study Design  ................................ ................................ ................................ .................. 29 
4.1. Overall  Design  ................................ ................................ ................................ ................ 29 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 29 
4.3. Justification for Dose  ................................ ................................ ................................ ......30 
4.4. End of Study Definition  ................................ ................................ ................................ ..30 
5. Study Population  ................................ ................................ ................................ ........... 31 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 31 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 32 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .36 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 36 
5.3.2.  Physical Activity  ................................ ................................ ................................ ............. 36 
5.4. Screen Failures  ................................ ................................ ................................ ................ 37 
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Part icipant  ................................ ................................ ................................ ................ 37 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 38 
6.1. Study Interventions Administered  ................................ ................................ .................. 38 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 39 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 39 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 39 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 40 
6.5. Dose Modification  ................................ ................................ ................................ .......... 40 
6.5.1.  Management of Participants with Gastrointestinal Symptoms  ................................ .......40 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 41 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...41 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....41 
6.8.1. Management of Incident Diabetes  ................................ ................................ .................. 42 
6.8.2.  Prohibited Concomitant Medications  ................................ ................................ ............. 43 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 44 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 44 
7.1.1.  Liver Chemistry Stopping Criteria  ................................ ................................ .................. 46 
7.1.2.  Temporary Discontinuation  ................................ ................................ ............................ 46 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ 47 
7.3. Lost to Follow up  ................................ ................................ ................................ ............ 48 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
6 8. Study Assessments and Procedures ................................ ................................ ............. 49 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....49 
8.1.1.  Primary Efficacy Assessment  ................................ ................................ ......................... 49 
8.1.2.  Secondary Efficacy Assessments  ................................ ................................ .................... 49 
8.1.3.  Exploratory Efficacy Assessments  ................................ ................................ ................. 51 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 53 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....53 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 53 
8.2.3.  Electrocardiograms (ECG) ................................ ................................ .............................. 53 
8.2.4.  Clinical Safety Laboratory Tests  ................................ ................................ .................... 53 
8.2.5.  Pregnancy Testing  ................................ ................................ ................................ ........... 54 
8.2.6. Suicidal Ideation and Behavior Risk Monitoring  ................................ ........................... 54 
8.3. Adverse Events, Serious Adverse Events, and Product 
Complaints  ................................ ................................ ................................ ...................... 55 
8.3.1.  Timing and Mechanism for Collecting Events  ................................ ............................... 55 
8.3.2.  Pregnancy  ................................ ................................ ................................ ........................ 57 
8.3.3.  Adverse Events of Special Interest  ................................ ................................ ................. 58 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 59 
8.4.1.  Bioanalytical Methods  ................................ ................................ ................................ ....59 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 59 
8.6. Genetics  ................................ ................................ ................................ .......................... 59 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 60 
8.8. Immunogenicity Assessments ................................ ................................ ......................... 60 
8.9. Health Economics OR Medical Resource Utilization and Health 
Economics  ................................ ................................ ................................ ....................... 60 
9. Statistical Considerations  ................................ ................................ ............................. 61 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....61 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..61 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 61 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 62 
9.3.1.  General Considerations  ................................ ................................ ................................ ...62 
9.3.2.  Primary Analysis  ................................ ................................ ................................ ............. 64 
9.3.3.  Analysis of Key Secondary Endpoints  ................................ ................................ ........... 64 
9.3.4.  Treatment Group Comparability  ................................ ................................ ..................... 65 
9.3.5.  Safety Analyses  ................................ ................................ ................................ ............... 65 
9.3.6.  Evaluation of Immunogenicity  ................................ ................................ ....................... 66 
9.3.7.  Other Analyses  ................................ ................................ ................................ ................ 67 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 67 
9.5. Sample Size Determination  ................................ ................................ ............................ 68 
10. Supporting Documentation and Operational Considerations  ................................ ..69 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 69 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 69 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 69 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 70 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 70 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
7 10.1.5.  Committees Structure ................................ ................................ ................................ ......70 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 71 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..72 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 73 
10.1.9.  Study and Site Start and Closure  ................................ ................................ .................... 74 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 74 
10.1.11.  Investigator Information  ................................ ................................ ................................ .74 
10.1.12.  Sample Retention  ................................ ................................ ................................ ............ 75 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 76 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event  ................................ ................................ ................................ ....78 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ 80 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 80 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ........... 81 
10.3.3.  Definition of Product Complaints  ................................ ................................ ................... 82 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 83 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 84 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 85 
10.3.7.  Special Safety Topics  ................................ ................................ ................................ ......85 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 88 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 88 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..89 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......91 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 92 
10.6.1.  Hepatic Evaluation Testing  ................................ ................................ ............................. 92 
10.6.2.  Close Hepatic Monitoring  ................................ ................................ ............................... 94 
10.6.3.  Comprehensive Hepatic Evaluation  ................................ ................................ ................ 94 
10.7.  Appendix 7: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Pr ocedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ............ 96 
10.8.  Appendix 8: Protocol GPIF Standardized Protocols for the 
Measurement of Height, Weight, Neck Circumference, Waist 
Circumference, Vital Signs, and Electrocardiogram  ................................ ...................... 97 
10.8.1.  Measuring Heig ht................................ ................................ ................................ ............ 97 
10.8.2.  Measuring Weight  ................................ ................................ ................................ ........... 97 
10.8.3.  Measuring Hip and Waist Circumference ................................ ................................ .......97 
10.8.4.  Measuring Neck Circumference  ................................ ................................ ..................... 98 
10.8.5.  Vital Sign Measurements (Blood Pressure and Heart Rate)  ................................ ........... 98 
10.8.6.  Electrocardiogram  ................................ ................................ ................................ ........... 99 
10.9.  Appendix 9: Provisions for Changes in St udy Conduct Due to the 
COVID -19 Pandemic  ................................ ................................ ................................ ....100 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
8 10.10.  Appendix 10: Abbreviations and Definitions  ................................ ............................... 104 
10.11.  Appendix 11: Country -Specific Requirements  ................................ ............................. 108 
10.11.1.  Germany  ................................ ................................ ................................ ........................ 108 
10.12.  Appendix 12: Protocol Amendment History  ................................ ................................ 112 
11. References  ................................ ................................ ................................ .................... 122 
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
9 1. Protocol Summary   
1.1. Synopsis   
Maste r Protocol Title:  A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide 
Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A 
Randomized, Double -Blind, Placebo -Controlled Trial (SURMOUNT -OSA)  
Brief  Title:  A Master Protocol for Tirzepatide in  Participants with  Obstructive Sleep Apnea and 
Obesity  
Rationale : 
Obstructive sleep apnea (OSA ) is a breathing disorder associated  with significant comorbidity 
and mortality . Current ly available therapeutic approache s have shown moderate success in 
treating the clinical signs and symptoms of O SA (that is,  snoring and excessive  daytime 
sleepiness ) but have failed to address the underlying pathophysiology of the disease and, more 
importantly, the cardiovascular (CV) morb idity and mortality associated with OSA . 
Tirzepatide is a dual GIP/GLP -1R agonist that has demonstrated statistically significant and 
clinically relevant lowering in HbA1c and dose -dependent weight loss in 5 Phase 3 trials that 
enrolled patients with type 2 diabetes mellit us (T2DM ) (Dahl et al. 2021 ; Frias et al. 2021;  Lilly 
2021 ; Ludvik et al. 2021; Rosenstock et al. 2021). Data from clinical studies show that a large 
proportion of participants  have significant body weight reduction with tirzepatide  treatm ent, 
suggesting that this agent may represent a promising pharmacologic treatment option that could 
reduce the frequency of apnea and hypopnea events as well as reduce weight, decrease blood 
pressure , and improve insulin resistance and dyslipidemia, which are all features associated with  
the increase  in CV morbidity and mortality  as seen  in people living with  OSA . 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
10 Objectives , Endpoint s, and Estimands : 
The following objectives and endpoints apply to both intervention -specific appendi ces (ISAs ). 
Primary Objective  Endpoints   
To demonstrate that tirzepatide at the MTD (10 mg or 15  mg) 
QW is superior to placebo for mean decrease  in AHI.  Change in AHI from baseline to Week 52  (events per 
hour) . 
Key Secondary Objective s (controlled for type I error)  Endpoints  
To demonstrate that tirzepatide at the MTD (10  mg or 15  mg) 
QW is superior to placebo for  From baseline to Week 52  
 Change  in AHI  
 A hierarchical assessment  of PRO s  Percent c hange in AHI  
 A hierarchical combination  of the following:  
o Change in FOSQ -10 score  
o Change in FOSQ (30 items)  Vigilance 
domain score  
o Change in FOSQ (30 items) Activity Level 
domain score  
 Clinically meaningful change in AHI   Percent of participants with ≥50% AHI 
reduction  
 Achieving OSA remission or mild nonsymptomatic  
OSA   Percent of participants with  
o AHI <5 or  
o AHI 5 -14 with ESS ≤10  
 Change in body weight  
  Percent change in body weight  
  
 Change in inflammatory status  
 
 Change in SBP   Change in hsCRP concentration  
From baseline to Week 48a 
 Change in SBP  
Abbreviations: AHI = Apnea -Hypopnea Index;  ESS = Epworth Sleepiness Scale;  FOSQ = Functional Outcomes of 
Sleep Questionnaire; hsCRP = high -sensitivity C reactive protein; MTD = maximum -tolerated dose; 
OSA  = obstructive sleep apnea;  PRO s = patient -reported outcomes; SBP = systolic blood pressure; QW = once 
weekly . 
a BP will be assessed at Week 48 because PAP suspension  at Week 52 may confound BP assessment . 
For estimands guiding statistical analyses, see Section 9.3.1 . 
Overall Design : 
The overall study design consists of 2 components:  
 Master Protocol: defines study elements common for both populations . 
 ISAs: provide detailed population -specific information.  
Study I8F-MC-GPIF  (GPIF)  is multicenter, randomized, parallel -arm, double -blind, placebo -
controlled , Phase 3 study  with 52-week  treatment  duration conducted under a basket -design, 
which will investigate the effects of treatment with weekly ( QW) tirzepatide  at the maximum 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
11 tolerated dose  (MTD ) (10 mg or 15 mg), compared with placebo in participants who have 
moderate -to-severe OSA  and obesity.  
One master protocol will support 2 studies/ISAs.  
 ISA 1  (GPI1)  will include participants who are unwilling or unable to use PAP therapy . 
 ISA 2 (GPI2) will include participants who are on PAP therapy  for at least 3 months at 
time of screening and plan to continue PAP  therapy  during the study . 
Participants will be assigned  to the ISA which reflects thei r current PAP usage . The participant 
will then be random ly assigned  1:1 to treatment or placebo . 
Number of Participant s: 
Approximately 412 participant s will be  random ly assigned to study intervention  across the entire 
master protocol , with approximately  206 participant s randomly assigned to study intervention in 
each ISA . See Section 9.5 for additional information.  
An upper limit of approximately 70% enrollment of male participants will be used to ensure a 
sufficiently large sample of female participants.  
Intervention Groups  and Duration : 
The study interventions are:  
 tirzepatide  at the MTD (10 mg or 15 mg) SC QW, or  
 placebo . 
The expected  total duration  of study participation for each participant, including screening and 
the post -treatment follow -up periods, is 60 weeks across the following study periods:  
 Screening: 4 weeks  
 Treatment : 52 weeks  
 Post-treatment  follow -up: 4 weeks  
The maximum duration of tre atment is 52 weeks.  
Data Monitoring Committee: Yes 
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
12 1.2. Schema   
Master Protocol and ISA Schema  
 
Abbreviations: ISA = intervention -specific appendix; MTD = maximum -tolerated dose; PAP = positive airway pressure.  
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
13 Dose Escalation and Visit  Schema  
 
Abbreviations : MTD = maximum -tolerated dose; QW  = once weekly . 
 
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
14 1.3. Schedule of Activities  (SoA)   
If Study Period I  - Screening takes longer or shorter than 4 weeks to complete, it will not be considered a protocol deviation.  Study 
Period I  - Screening should not exceed 6 weeks unless approval from the sponsor is received.  
Visit  procedures may be conducted over more than 1 day as long as all activities are c ompleted within the allowable visit tolerance 
period  of each visit . 
Study Period II  - Treatment: For early discontinuations (ED)  from study that occur before the last visit in treatment period, see the 
activities listed for ED in this table.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
15  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
Informed consent  X              The informed consent must be signed before any 
protocol -specific tests/procedures are performed.  
Inclusion and 
exclusion criteria, 
review and confirm  X X            Inclusion/Exclusion criteria should be confirmed  prior 
to drug assignment and administration of first dose of 
study intervention.  
Demographics  X             Includes ethnicity , year of birth, gender (sex) , and 
race.  
Preexisting 
conditions and 
medical history, 
including relevant 
surgical history  X             All conditions ongoing and relevant past surgical and 
medical history should be collected.  
Prespecified 
medical history  X             Should include, but not be limited to, collecting 
diagnosis of OSA and obesity -related health 
problems.  
Prior treatments for 
indication  X             Include OSA and obesity .  
Substance use 
(alcohol, caffeine, 
tobacco use)  X              
Concomitant 
medications  X X X X X X X X X X X X X  
AEs  X X X X X X X X X X X X X Any events that occur after signing the informed 
consent are considered AEs as defined in Section 
8.3.1 . Additional data are collected for certain AEs . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
16  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
Physical Evaluation   
Height  X               
Weight  X X X X X X X X X X X X X Weight measurements should be obtained  per the 
instructions in  Section  10.8.  
Waist 
circumference   X     X    X X X Waist circumference  should  be obtained per the 
instructions in Section 10.8.  
Hip circumference   X     X    X X X Hip circumference should be obtained per the 
instructions in Section 10.8. 
Neck circumference   X     X    X X X Neck circumference should be obtained per the 
instructions in Section 10.8. 
Vital signs X X X X X X X X X X X X X Includes PR and BP. Measured after participant has 
been sitting at least 5 minutes. Vital -sign 
measurements should be taken before obtaining an 
ECG tracing and before collection of blood samples 
for laboratory testing . See Section s 8.2.2  and 10.8. 
Complete physical 
examination  X             The complete physical exam ination  is performed 
(excludes pelvic, rectal, and breast exam ination s 
unless clinically indicated) .  
Symptom -directed 
physical assessment   X (refer to Comment)   Symptom -directed physical assessment from V2 
through  V11 and ED  will be conducted at the 
discretion of the PI , as indicated based on participant 
status and standard of care.  
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
17  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
May be performed by  qualified personnel per local 
regulations.  
12-lead ECG (local)  X          X  X  ECG measurements should be obtained per the 
instructions in Section 8.2.3 .  
Wearable Devices and PSG Assessments   
Schedule Sleep 
Center Study for 
PSG X     X     X    PSG results must be reviewed to confirm eligibility  
prior to randomization.  
Sleep Center Study 
for PSG  X      X     X   PSG at V7 and 11 may be scheduled for any day +/ - 
14 days.  
Participant wears 
the WatchPat300  X  X  X  X    X   Applicable only to participants in GPI1 (off PAP).  
Training documents will detail information on the 
dispensation, wearing, and return process.  
Participant wears 
actigraphy (AX6) 
device   X  X  X  X    X   Training documents will detail information on the 
dispensation, wearing,  and return process.  
Participant Education and Supplies  
eDiary education  X             Additional training can be repeated, as needed.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
18  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
Train participant on 
study intervention  
administration   X            Re-training is available anytime .  
Review Lifestyle 
Program 
instructions   X X X X X X X X X X  X  Diet and exercise goals established during the lifestyle 
consultation and the importance of adherence to the 
lifestyle component of the trial will be reinforced at 
each trial contact by study staff.   
Participant Diary  
Participant diary 
dispensed  X             Includes the following :  
Electronic diaries: Sleep diary; Dosing diary; 
Hypoglycemic events (when applicable), PAP 
adherence (for GPI2 only ). 
Paper diary: Patient Diet and Exercise diary  
Diary compliance 
check   X X X X X X X X X X X   
Diary return            X X   
Patient -Reported Out comes (Electronic)  
Complete prior to any clinical -administered assessments   
ESS  X  X  X  X    X X  
When the PROs are scheduled for visits at which the 
PSG will be done, they should be completed on the 
same day as PSG and in the following order  (FOSQ , 
ESS, PROMIS Short Form v1.0 Sleep Disturbance 8b, 
PROMIS Short Form v1.0 Sleep -related Impairment 
8a, PGIS, PGIC, SF -36v2 acute form, and EQ-5D-EQ-5D-5L X          X X  
FOSQ  X    X  X    X X  
PGIS  (OSA 
Symptom Scales)  X  X  X  X    X X  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
19  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
5L). Completing the PRO assessments on the next day 
after P SG is not considered a protocol violation.  
PGIC (OSA 
Symptom Scales)    X  X  X    X X   
PROMIS Short  
Form v1.0 Sleep  
Disturbance 8b  X  X  X  X    X X   
PROMIS Short 
Form v1.0 Sleep -
related Impairment 
8a X  X  X  X    X X   
SF-36v2 , acute  X      X    X X   
PHQ -9 X X     X    X X  The PHQ -9 should be administered after assessment 
of AEs, if both collected on the same day . 
PHQ-9 at V7 and V11 may be scheduled for any day 
+/- 14 days.  
Clinician -Administered Assessments (Paper)   
C-SSRS 
screening/ baseline  X              The C -SSRS should be administered after assessment 
of AEs, if both collected on the same day . 
The C -SSRS since last visit is adapted for the 
assessment of the ideation and behavior categories 
only. The Intensity of Ideation and Lethality of 
Behavior sections are removed.  C-SSRS (since last 
visit version)   X     X    X X  
Laboratory Tests and Sample Collections  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
20  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
Hematology  X    X   X X  X X X  
HbA1c  X X   X   X X  X X X  
Clinical chemistry 
(includes glucose)  X X   X   X X  X X X  
Lipid panel   X      X   X X X  
hsCRP   X      X   X X   
Serum pregnancy  X             Only for WOCBP and females with a history of tubal 
ligation. See Section  10.4, Appendix  4. 
Urine pregnancy 
(local)   X   X   X X  X X  A urine pregnancy test must be performed at V2 with 
the result available prior to first dose/injection of 
study intervention  for WOCBP  only. Additional 
pregnancy tests (beyond those required per the SoA) 
should be performed at any time during the trial if a 
menstrual period is missed, there is clinical suspicion 
of pregnancy, or as required by local law or 
regulation.  
FSH X             Optional; performed as needed to confirm 
postmenopausal status. See Section 10.4, Appendix 4. 
Insulin   X      X   X X X  
C-Peptide   X      X   X X X  
Free fatty acids  X      X   X X X  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
21  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
Cystatin -C X       X   X X X  
Calcitonin  X          X X X  
Pancreatic amylase  X    X   X   X X X  
Lipase  X    X   X   X X X  
TSH  X              
eGFR  X X   X   X X  X X X Calculated using CKD -EPI method.  
UACR  X X   X   X X  X X X  
PK samples   X X  X   X   X X X PK samples to be collected predose and close to ADA 
samples.  
Immunogen icity 
(ADA) samples   X X  X   X   X X X In the event of systemic drug hypersensitivity 
reactions (immediate or nonimmediate), additional 
unscheduled samples should be collected as detailed 
in Section 10.3.7.2  (Hypersensitivity Reactions ). 
Immunogenicity samples and PK samples for 
immunogenicity must be predose . 
Stored Samples  
Genetics sample   X            Sample can be obtained at or after the specified visit.  
Exploratory 
biomarker samples   X      X   X X X  
Randomization and Dosing  
Register visit with 
IWRS  X X X X X X X X X X X X X  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
22  Study 
Period I - 
Screening  Study Period II  - Treatment  Study 
Period III  
- Post-
Treatment 
Follow -up Comments  
Visit number  1 2 3 4 5 6 7 8 9 10 11 ED 801  
Weeks from 
randomization  -4 0 4 8 12 16 20 24 36 48 52 - See 
footnote  a  
Visit interval 
tolerance (days)  -14 to + 21 – ±3 ±3 ±3 ±3 ±7 ±3 ±7 ±3 ±7 ±7 ±3  
Fasting Visit   X X X X X X X X X X X X See footnote b. 
ISA assignment via 
IWRS  X              
ISA treatment 
randomization via 
IWRS   X             
Observe participant 
administer study 
intervention   X            Participants should administer their first dose of study 
intervention  at the end of the V2, after other study 
procedures are completed . 
Dispense study 
drug via IWRS   X X X X X X X X X     
Dispense study 
drug to participant 
(for at home 
dosing)   X X X X X X X X X     
Dispense ancillary 
supplies to 
participant   X            Dispensation of ancillary supplies may vary beyond 
V2 based on expiry dating of applicable supplies 
and/or participant  needs . 
Participant returns 
all unused study 
intervention     X X X X X X X X X X   
Assess study 
intervention  
compliance    X X X X X X X X X X   
Approved on 02 Jun 2023 GMT
CONFIDENTIAL  Master Protocol I8F -MC-GPIF (c) 
23 Abbreviations: ADA = antidrug antibody; AEs = adverse events; AX6 = Axivity 6;  CKD EPI = Chronic Kidney Disease Epidemiology; hsCRP =  high sensitivity  
C-reactive protein;  C-SSRS = C olumbia -Suicide Severity Rating Scale ; ECG = electrocardiogram;  ED = early discontinuation; eGFR = estimated glomerular 
filtration rate ; EQ-5D-5L = EuroQo l - 5 Dimension - 5 Level; ESS = Epworth Sleepiness Scale; FOSQ = Functional Outcomes of Sleep Questionnaire;  FSH = 
follicle -stimulating hormone ; HbA1c = hemoglobin A1c ; ISA = intervention -specific appendi x; IWRS = interactive web -response system ; OSA = obstructive 
sleep apnea; PHQ = Patient Health Questionnaire -9; PGIC  = Patient Global Impression of Change; PGIS  = Patient Global Impression of Status;  
PK = pharmacokinetic ; PSG = polysomnography;  PR = pulse rate; PRO = patient reported outcome; PROMIS = Patient-Reported Outcomes Measurement 
Information System ; SF-36v2 = Short -Form 36  version 2;  SoA = schedule of activities; TSH = thyroid -stimulating hormone ; UACR = urinary 
albumin/creatinine ratio ; V = visit; WOCBP = wom an of childbearing potential . 
a Post-treatment follow -up occurs approximately 4 weeks after the participant’s final treatment period  visit.  
b Fasting visit: On all office visits, study participants should be reminded to report to the site before taking study intervention  in a fasting con dition, after a 
period of approximately 8 hours without eating, drinking (except minimal amount of water , as needed ), or any significant physical activity.  
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 24 2. Introduction   
2.1. Study Rationale   
Obstructive sleep apnea is a breathing disorder associated with significant comorbidity and 
mortality. Currently available therapeutic approaches have shown moderate success in treating 
the clinical signs and symptoms of OSA (that is, snoring and excessive  daytime sleepiness) but 
have failed to address the underlying pathophysiology of the disease and, more importantly, the 
CV morbidity and mortality associated with OSA.  
Tirzepatide is a dual GIP/GLP -1R agonist that has demonstrated statistically significan t and 
clinically relevant lowering in HbA1c and dose -dependent weight loss in 5 Phase 3 trials that 
enrolled patients with T2DM ( Dahl et al. 2021; Frias et al. 2021;  Lilly 2021 ; Ludvik et al. 2021; 
Rosenstock  et al. 2021). Data from clinical studies show that a large proportion of participants  
have significant body weight reduction with tirzepatide treatment, suggesting that this agent may 
represent a promising pharmacologic treatment option that could reduce the frequency of apnea 
and hypopnea events as well as reduce weight, decrease BP, and improve insulin resistance and 
dyslipidemia, which are all features associated with  the increase in CV morbidity and mortality 
as seen in people living with OSA . 
2.2. Backgrou nd  
Obstructive sleep apnea is a serious medical condition with a limited number of therapeutic 
options and high unmet need. OSA  is a well -established risk factor for morbidity an d mortality 
from CV and other metabolic diseases; further, it negatively affects daily life of patients 
(Tietjens et al. 2019; Gottlieb and Punjabi 2020).  
Treatments for OSA include behavioral measures like weight loss programs, medical devices 
such as PAP , oral appliances or hypoglossal nerve stimulation, and surgery, including bariatric 
surgery in people living with obesity and OSA . Weight loss through  caloric restriction and  
lifestyle interventions improves AHI, cardiometabolic comorbidities, and quality  of life. 
Although a limited number of studies have investigated the effect of pharmacological weight -
loss therapy, their results support that adding weight -loss medication to lifestyle intervention 
reduces AHI and improves sleep quality and possibly other  OSA -related outcomes. As such, 
standard of care recommends a prioritization of weight loss for patients with OSA and obesity or  
who are  overweight , including consideration for FDA -approved  antiobesity pharmacotherapy  
(Hudgel et al. 2018 ). Bariatric surgery  is available for patients with severe obesity and  can 
dramatically improve OSA  (Currie et al. 2021). However, such surgical procedures are  
associated with greater risk for perioperative and postoperative complications (Opperer et al. 
2016).  
Positiv e airway pressure  is the first-line treatment for moderate -to-severe and symptomatic mild 
OSA . Despite good clinical efficacy for the signs and symptoms  of OSA , randomized controlled  
studies  in PAP therapy have failed to show improvements in nonsleep -related outcomes linked to 
OSA  such as stroke, heart attack, diabetes and depression  (AHRQ 2021) . It is thought inadequate 
PAP therapy adherence may explain why randomized clinical trials  have failed to demonstrate 
benefit (Gottlieb and Punjabi 2020 ). Nonadhere nce to PAP therapy is a major clinical challenge  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 25 and studies have shown wide variability in adherence, ranging from 29% to 83% (Weaver and 
Grunstein  2008) . Currently, there are only few pharmacologic alternatives indicated for 
symptoms in patients with  OSA and none are disease  modifying . 
There is significant unmet need in treatment of patients with OSA. Tirzepatide, a GIP and 
GLP -1R dual agonist, has the potential to provide benefit to patients  with OSA  who have obesity  
by reducing weight, which may red uce the frequency of apnea and hypopnea events, decreasing 
BP, and improving insulin resistance and dyslipidemia .  
2.3. Benefit/Risk Assessment   
More detailed information about the kno wn and expected benefits and risks and reasonably 
expected  AEs of tirzepatide  may be found in the IB. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 26 3. Objectives , Endpoints , and Estimands   
The following  objectives and endpoints apply to both ISAs.  
Primary Objective  Endpoints   
To demonstrate that tirzepatide at the MTD  (10 mg or 15  mg) 
QW is superior to placebo for mean decrease in AHI.  Change in AHI from baseline to Week 52  (events per 
hour) . 
Key Secondary Objective s (controlled for type I error)  Endpoints  
To demonstrate that tirzepatide at the MTD (10  mg or 15  mg) 
QW is superior to placebo for  From baseline to Week 52  
 Change  in AHI  
 A hierarchical assessment  of PROs   Percent c hange in AHI  
 A hierarchical combination of the following:  
o Change in FOSQ -10 score  
o Change in FOSQ  (30 items)  Vigilance 
domain score  
o Change in FOSQ (30 items) Activity Level 
domain score  
 Clinically meaningful change in AHI   Percent of participants with ≥50% AHI 
reductio n 
 Achieving OSA remission or mild nonsymptomatic 
OSA   Percent of participants with  
o AHI <5 or  
o AHI 5 -14 with ESS ≤10  
 Change in body weight  
  Percent change in  body weight  
  
 Change in inflammatory status  
 
 Change in SBP  
  Change in hsCRP concentration  
 
From baseline to Week 48a 
 Change in SBP  
Other Secondary Objective s 
 Endpoints  
To demonstrate that tirzepatide at the MTD (10  mg or 15  mg) 
QW is superior to placebo for  From baseline to Week 52  
 Change in excessive daytime sleepiness   Change in ESS score  
 Change in patient -reported functional status as 
assessed by FOSQ (30 items)   Change in all other FOSQ  domain score s 
 Change in body weight   Percent of participants who achieve  
o ≥10% body weight reduction  
o ≥15% body weight reduction  
o ≥20% body weight reduction  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 27  Change in l ipid parameters   Change in  
o HDL -cholesterol  
o non-HDL -cholesterol  
o triglycerides  
  
 Change in PROs  
  Change in : 
o PROMIS Sleep -related impairment 
short form 8a score  
o PROMIS Sleep disturbance short form 
8b score  
o SF-36v2 acute form domain scores  
 Percent of participants with improved 
categorical shift  in: 
o PGIS-OSA Sleepiness  
o PGIS -OSA Fatigue  
o PGIS -OSA Snoring   
 Insulin  
 Hypoxic burden  
 Change in DBP   Change in fasting insulin  
 Change in  SASHB (% min/hour) 
From baseline to Week 48a 
 Change in DBP 
Exploratory  Objective s  Endpoints  
To demonstrate that tirzepatide at the MTD (10 mg or 15 mg) 
QW is superior to placebo for  From baseline to Week 52  
 Change in PRO s  Change in  
o EQ-5D-5L utility index  
o EQ-VAS scores  
 Percent of participants  with improved 
categorical shift in:  
o PGIC -OSA Sleepiness  
o PGIC -OSA Fatigue  
o PGIC -OSA Sleep quality  
o PGIC -OSA Snoring  
 To evaluate the effect of tirzepatide on sleep 
parameters as measured by Actigraphy  (AX6)   Mean change from baseline to endpoint 
assessment in  
o Daytime sleep duration  
o Daily step counts  
o Average acceleration  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 28 Abbreviations: AHI  = Apnea -Hypopnea Index ; AX6 = Axivity 6; DBP  = diastolic blood pressure ; ESS  = Epworth 
Sleepiness Scale; EQ-5D-5L = EuroQol - 5 Dimension - 5 Level; EQ-VAS = EuroQol Visual Analogue Scale ; 
FOSQ  = Functional Outcomes of Sleep Questionnaire; HDL  = high-density lipoprotein; hsCRP  = high-sensitivity 
C reactive protein ; MTD  = maximum -tolerated dose ; OSA = obstructive sleep apnea ; PGIC -OSA = Pati ent 
Global Impression of Change – Obstructive Sleep Apnea; PGIS -OSA  = Patient Global Impression of Status – 
Obstructive Sleep Apnea ; PRO s = patient -reported outcomes; PROMIS = Patient -Reported Outcomes 
Measurement Information System ; SBP = systolic blood pr essure; SF -36v2  = Short -Form  36 version 2 , SASHB 
= sleep apnea -specific hypoxic burden ; QW = once weekly.  
a BP will be assessed  at Week 48  because PAP suspension  at Week 52 may confound BP assessment . 
 
For estimands  guiding statistical analyses , see Section 9.3.1 . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 29 4. Study Design   
4.1. Overall  Design   
Study I8F-MC-GPIF  (GPIF) is a multicenter, randomized,  parallel -arm, double -blind, placebo -
controlled Phase 3 study to evaluate the efficacy and safety of tirzepatide at the MTD (10 mg or 
15 mg) QW versus placebo in participants who have obesity and moderate -to-severe OSA . 
This basket -type master protocol will investigate 2 participant populations, described in 2 ISA s: 
 GPI1 will include participants who are unwilling or are unable to use PAP therapy . 
 GPI2 will include participants who are on PAP therapy  for at least 3 months at time of 
screening and plan to  continue PAP  therapy  during the study.  
Participants  to be assigned  to whichever ISA they qualify for. Participants will then be randomly 
assigned to: 
 tirzepatide  at the MTD (10 mg or 15 mg) SC QW, or  
 placebo . 
The expected  total duration of study participation for each participant, including screening and 
the post -treatment follow -up periods, is 60 weeks across the following study periods:  
 Screening:  4 weeks  
 Treatment : 52 weeks  
 Post-treatment follow -up: 4 weeks  
The maximum  duration of treatment is 52 weeks. Procedures and assessments for each visit are 
presented in the SoA, Section 1.3. 
4.2. Scientific Rationale for Study Design   
The basket trial design employs a single overarching trial structure as a means to implement 
multiple investigations (Woodcock and LaVange 2017). Such approaches often allow for more 
streamlined  and coordinated clinical trial logistics and consistency in d ata collection methods.  
The 2 studies associated with the master protocol, also called “Intervention -Specific 
Appendices” (ISAs), will describe any objectives, endpoints  and efficacy assessments specific to 
each study population. ISA refer s to specific pop ulation and background intervention, as defined 
by inclusion criteria. Used together, the master protocol and the 2 ISAs will describe the 
investigations to be conducted.  
ISA 1 and ISA 2 represent different populations with different treatment needs, and i t is 
anticipated that tirzepatide  may meet the needs of each participant  group.  
Inclusion of a placebo treatment arm is acceptable because there are no currently effective 
disease -modifying treatments for OSA ; this approach is in agreement with the use of placebo 
described in the Declaration of Helsinki (WMA 2013). The use of a placebo comparator in Study 
GPIF  is needed to determine the efficacy and safety of tirzepatide  therapy.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 30 4.3. Justification for Dose   
Tirzepatide doses of up to 15 mg administered SC QW will be evaluated in this study. 
Participants  may be treated with lower maintenance dose of 10 mg if they do not achieve full 
dose es calation to 15 mg and/or do not tolerate 15 mg.  
These doses and associated escalation schemes were selected based on assessment of safety, 
efficacy (weight loss), and GI tolerability data in Phase 1, 2, and 3 studies in patients with 
T2DM, followed by expo sure-response modeling of the data that predicted weight loss in 
patients with overweight or obesity.  
Dosing algorithms starting at a low dose of 2.5 mg accompanied by dose escalation of 2.5 mg 
increments  every 4 weeks should permit time for development of tolerance to GI events and are 
predicted to minimize GI tolerability concerns.  
Similar to the GLP -1RA class, most of the tirzepatide  AEs were dose-dependent and GI-related , 
consisting mainly of nausea, v omiting, and diarrhea. In general, these events were mild or 
moderate  in severity, with few severe episodes, and transient.  
Tirzepatide  doses of 10 mg and 15 mg as MTD  were  selected based principally on the following 
criteria : 
 each dose provides robust wei ght loss relative to placebo  
 the percent of participant s achieving ≥10% weight loss is higher with 15 mg than 10  mg, 
and 
 safety and tolerability were supported by Phase 3 results  in T2DM . 
The proposed tirzepatide  maintenance dose of up to 15 mg using a dos e-escalation regimen is 
expected to safely maximize the potential for weight loss while minimizing GI tolerability 
concerns as has been achieved for approved GLP -1 RA drugs. The subsequent benefit of weight 
loss sho uld result  in clinically meaningful impro vements in AHI.  
4.4. End of Study  Definition   
A participant is considered to have completed the study if they have completed all required 
phases of the study including the last visit or the last scheduled procedure shown in the SoA. The 
end of the study for each ISA is defined as the date of the last visit of the last participant in the 
study or last scheduled procedu re shown in the SoA for the last participant in the trial globally. 
The end of study timing for each ISA is independent of the other ISA end of study timing.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 31 5. Study Population   
Prospective  approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants a re eligible to be included in the study only if all of the following criteria apply : 
Age 
1. Participant must be at least 18 (or the legal age of consent in the jurisdiction in which the 
study is taking place ) years of age , inclusive, at the time of signing the informed consent.  
Type of Participant and Disease Characteristics  
2. Previously diagnosed moderate -to-severe OSA with an AHI ≥15, as diagnosed with PSG, 
home sleep apnea test ( HSAT ), or other method that meets local guid elines prior to Visit 
1. See Section 10.10  for definitions of apnea and hypopnea.  
3. AHI ≥15 on PSG as part of the trial at Visit 1 . 
4. In the investigator’s opinion, are well -motivated, capable, and willing to  
 learn how to self -inject study intervention , as required for this protocol (visually 
impaired  persons who are not able to perform the injections must have the assistance 
of a sighted indiv idual trained to inject study intervention ; persons with physical 
limitations who  are not able to perform the injections must have the assistance of an 
individual trained  to inject study intervention ) 
 inject study intervention  (or receive an injection from  a trained individual if visually  
impaired or with physical limitations) , and  
 follow study procedures for the duration of the study, including, but not limited to: 
follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain 
a study diary, and complete required questionnaires . 
Weight  
5. BMI ≥30 kg/m2. 
6. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight . 
Sex and Contraceptive/Barrier Requirements  
7. Male s and females may participate in this trial.  
Female participants must not be pregnant, intending to be pregnant,  breastfeeding , or 
intending to breastfeed . 
Contraceptive use by participants should be consistent with local regulations regarding 
the methods of contraception for those participating in c linical studies . For definitions 
and the contraception requirements of this protocol, see  Appendix  4 (Section  10.4) . 
Informed  Consent  
8. Capable of giving signed informed consent as described in Appendix 1  (Section 10.1), 
which includes compliance with the requirements and restrictions listed in the ICF and in 
this protocol . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 32 5.2. Exclusion Criteria   
Participants  are excluded from the study if any of the following criteria apply:  
Medical Conditions  
Diabetes -related  
9. Have T1DM or T2DM, history of ketoacidosis, or hyperosmolar state/coma . 
10. HbA1c ≥ 6.5% (≥ 48 mmol/mol) at Visit 1 . 
OSA-related  
11. Any previous or planned  surgery for sleep apnea or major ear, nose or throat  surgery , 
including tonsillectomy and adenoidectomy  that still may affect  breathing at time of Visit 
1. Inclusion of a participant  with more minor ear, nose or throat  surgery ( for example , 
deviated septum) will be at the investigator’s discretion . 
12. Significant craniofacial abnormalities that may affect breathing at time of Visit 1 . 
13. Diagnosis of Central or Mixed Sleep Apnea  with % of mixed or central 
apneas/hypopneas  ≥50%, or diagnosis of Cheyne Stokes  Respiration.  
14. Diagnosis of Obesity Hypoventilation Syndrome  or daytime hypercapnia . 
15. Active  device  treatment of OSA other than PAP therapy  (for example , dental appliance), 
or other  treatment, that in the opinion of the investigator, may interfere with study 
outcomes, unless willing to stop treatment at Visit 1 and through out the study . 
16. Respiratory and neuromuscular diseases that could interfere with the results of the trial in 
the opinion of the investigato r. 
Obesity -related  
17. Have a self-reported change in body weight >5 kg within 3 months prior to screening . 
18. Have a prior or planned surgical treatment for obesity (excluding liposuction or 
abdominoplasty if performed more than 1 year prior to screening) . 
19. Have or plan to have endoscopic and/ or device -based therapy for obesity or have had 
device  removal within the last 6 months (for example, muco sal ablation, gastric artery  
embolization, intragastric balloon , and duodenal -jejunal bypass sleeve) . 
Other medical  
20. History of cl inically relevant medical, behavioral, or psychiatric disorder , other than 
OSA , that is associated with insomnia or excessive sleepiness . 
21. Impaired renal function, defined as eGFR <30  mL/min/1.73 m2. 
22. Have a known clinically significant gastric emptying abnormality (for examp le, severe 
gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI 
motility . 
23. History of chronic or acute pancreatitis . 
24. Thyroid -stimulating hormone outside of the range of 0.4 to 6.0 mIU/L at the screening 
visit. 
Note:  Participant s receiving treatment for hypothyroidism may be included, provided 
their thyroid hormone replacement dose has been stable for at least 3 months.  
Note:  TSH values above the normal range can, in some patients, suggest subclinical 
hypothyroidism. If, in the investigator’s opinion, the participant has subclinical 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 33 hypothyroidism and may require initiation of thyroid hormone replacement during the 
course of t he study, the participant  should be excluded from the study.  
25. Have obesity induced by other endocrinologic disorders (for example, Cushing 
Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, 
Melanocortin 4 Receptor deficiency or Prader -Willi Syndrome) . 
26. Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at 
significant risk for suicide . 
27. Have answered “yes” to either Question 4 or Question 5 on the “Suicidal Ideation” 
portion of the C -SSRS or 
have answered “yes” to any of the suicide -related behaviors on the “suicidal behavior” 
portion of the C -SSRS,  
and the ideation or behavior occurred within the past month . 
28. PHQ -9 score of 15 or more at Visit 1 or 2, prior to randomization . 
29. Uncontrolled hypertension ( SBP ≥160 mmHg and/or DBP  ≥100  mmHg) at Visit 1.  
30. Any of the following CV conditions less than 3 months prior to randomization: acute MI, 
cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive 
heart failure.  
31. History of ( less than 3 months prior to Visit 1) or planned CV procedure . 
32. Heart failure, including New York Heart Association  Functional Classification Class IV  
33. Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than 
nonalco holic fatty liver disease, or any of the following, as determined by the central 
laboratory during screening:  
 ALT level >3.0X the ULN for the reference range  
 ALP level >1.5X the ULN for the reference range , or 
 TBL level >1.2X the ULN for the reference rang e (except for cases of known 
Gilbert’s Syndrome) . 
Note : Participants with nonalcoholic fatty liver disease are eligible to participate in 
this trial if their ALT level is ≤3.0X the ULN for the reference range . 
34. Have a calcitonin level (at Visit 1) of:  
a. ≥20 ng/L at Visit 1, if eGFR ≥60 mL/min/1.73 m2 
b. ≥35 ng/L at Visit 1, if eGFR <60 mL/min/1.73 m2 
35. Have a family or personal history of medullary thyroid carcinoma  or multiple endocrine 
neoplasia  syndrome type 2. 
36. Have a history of an active or untreated malig nancy or are in remission from a clinically 
significant malignancy (other than basal - or squamous -cell skin cancer, in situ 
carcinomas of the cervix, or in situ prostate cancer) for less than 5 years . 
37. Have any other condition not listed in this section (fo r example, hypersensitivity or 
intolerance) that is a contraindication to GLP -1R agonists . 
38. Have a history of any other condition (such as known drug or alcohol abuse, diagnosed 
eating disorder, or other psychiatric disorder) that, in the opinion of the inv estigator, may 
preclude the participant from following and completing the protocol . 
39. Have history of use of marijuana less than 3 months of V1 and unwillingness to abstain 
from marijuana use during the trial. Participants should also refrain from use of 
cannabidiol oil for the duration of the study . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 34 40. Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an 
organ transplant . 
41. Requires the use of supplemental oxygen . 
 
Prior/Concomitant Therapy  
42. Are receiving or have received within 3 months prior to screening chronic (>2 weeks or  
14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, int ra- 
articular, or inhaled preparations) or have evidence of a significant, active autoimmune 
abnormality (for example, lupus or rheumatoid arthritis) that has required (within the last  
3 months) or is likely to require, in the opinion of the investigator, concurrent treatment 
with systemic glucocorticoids (excluding topical, intraocular, intranasal, intra -articular , or 
inhaled preparations) in the next 12 months .  
43. Have current or history of ( less than 3 months prior to Visit 1) treatment with 
medications th at may cause significant weight gain, including but not limited to: tricyclic 
antidepressants, atypical antipsychotic and mood stabilizers , for example:  
 imipramine  
 amitriptyline  
 mirtazapine  
 paroxetine  
 phenelzine  
 chlorpromazine  
 thioridazine  
 clozapine  
 olanzapine  
 valproic acid and its derivatives  
 lithium  
Note:  Selective serotonin reuptake inhibitors are permitted,  except for  paroxetine.  
44. Have taken , less than 3 months prior to Visit 1, medications (prescribed or over -the-
counter) or alternative remedies intended to promote weight loss.  Examples include, but 
are not limited to : 
 Saxenda® (liraglutide 3.0 mg)  
 Xenical®/Alli® (orlistat)  
 Meridia® (sibutramine)  
 Acutrim® (phenylpropanolamine)  
 Sanorex® (mazindol)  
 Adipex® (phentermine)  
 BELVIQ® (lorcaserin)  
 Qsymia® (phentermine/topiramate combination)  
 Contrave® (naltrexone/bupropion)  
 Pramlintide  
 Zonisamide  
 Topiramate  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 35  Wegovy®  
 Any glucose -lowering medication, including metformin  
Note:  Use of metformin or any other glucose -lowering medication, whether prescribed 
for pol ycystic ovary syndrome or diabetes prevention is not permitted.  
45. Use of stimulants  less than 3 months prior to V isit 1 (for example , modafinil, 
armodafinil, solriamfetol, pitolisant, amphetamine, dextroamphetamine, 
dexmethylphenidate, methylph enidate,  and lisdexamfetamine) . 
46. Use of hypnotics , mirtazapine, opioids, trazodone  less than 3 months prior to Visit 1 . 
47. Use of GLP -1 RA less than 3 months prior to V isit 1. 
48. Criterion 48 is deleted . 
49. Use of any over-the-counter  or prescription medications that could affect the evaluation 
of excessive sleepiness , per investigator discretion . 
50. Unwillingness to discontinue over -the-counter (herbal or supplemental) medication that, 
in the opinion of the investigator, can interfere wi th the study . 
Prior/Concurrent Clinical Study Experience  
51. Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically or medically compatible 
with this study.  
52. Previously random ly assigned  to study intervention in  this study or any other study 
investigating tirzepatide . 
53. Have participated, within the last 30 days in a clinical trial involving a study intervention . 
If the previous  study intervention  is scientifically or medically incompatible with this 
study and has a long half -life, 3 months or 5 half -lives (whichever is longer) should have 
passed prior to screening (participation in observational studies may be permitted upon 
review of the observationa l study protocol and approval by the sponsor).  
54. Are Lilly employees or employees of third -party organizations involved with the study.  
55. Are investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is d efined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.  
56. Have a ny medical condition that, in the opinion of the investigator, would be a 
contra indication  to participation in the trial  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 36 5.3. Lifestyle Considerations   
Per the So A (Section 1.3), participants  will consult with study personnel  experienced  in diet and 
exercise counseling  to receive lifestyle  program instructions  at timepoints indicated in the SoA. 
Diet and exercise go als and the importance of adherence to the lifestyle program will be 
reinforced at each trial contact by study staff.  
5.3.1.  Meals and Dietary Restrictions   
At Visit 2 and subsequent vis its, participants will consult with study personnel experienced in 
diet and exercise counseling to receive lifestyle program instructions at timepoints indicated in 
the SoA. Dietary counseling will consist of advice on healthy food choices and focus on cal orie 
restriction using a hypocaloric diet with macronutrient composition of:  
 maximum 30% of energy from fat  
 approximately 20% of energy from protein  
 approximately 50% of energy from carbohydrates  
 an energy deficit of approximately 500 kcal/day compared to the participant’s estimated 
TEE 
To encourage adherence, it is recommended that a 3-day diet and exercise diary be completed 
prior to each counseling visit.  During each visit, the participant’s diet is reviewed and advice to 
maximize adherence is provided if needed.  
The hypocaloric diet is continued after randomization and throughout the treatment period. If a 
BMI ≤22  kg/m2 is reached, the recommended energy intake should be recalculated with no kcal 
deficit for the remainder of the trial.  
Total energy  expenditure is calculated by multiplying the estim ated Basal Metabolic Rate (BMR) 
(see table below) with a Physical Activity Level value of 1.3 (FAO/WHO/UNU 200 4), which 
reflects  an inactive lifestyle. This calculation provides a conservative estimate of caloric 
requirements:  
                        TEE (kcal/day)  = BMR X 1.3 
 
Equations for estimating BMR in kcal/daya 
Sex Age BMR  (kcal/day) 
Men 18-30 years  15.057 X actual weight in kg  + 692.2  
 31-60 years  11.472 X actual weight in kg +  873.1  
 >60 years  11.711 X actual weight in kg +  587.7  
Women  18-30 years  14.818 X actual weight in kg  + 486.6  
 31-60 years  8.126 X actual weight in kg +  845.6  
 >60 years  9.082 X actual weight in kg +  658.5  
Abbreviation s: BMR = basal metabolic rate ; WHO  = World Health Organization . 
aRevised WHO equations (Adapted from: FAO/WHO/UNU 2004) . 
5.3.2.  Physical Activity   
At Visit 2 and all subsequent visits, p articipants will be advised to increase their physical activity 
to at least 150 minutes per week . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 37 5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently randomly assigned to study intervention  in the study . A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participant s to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and 
to respond to queries from regulatory authorities. Minimal in formation includes demography, 
screen failure details, eligibility criteria, and any SAE . 
Individuals who have history of marijuana use less than 3 months of V isit 1 may be rescreened  
once provided the individual is willing to abstain from marijuana use du ring the trial . Rescreened 
participants should be assigned a new participant number for every screening/rescreening event.  
See Section  5.4 of the respective ISA’s for additional  rescreening guidelines.  
5.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention 
of a Participant   
Not applicable.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 38 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participa nt 
according to the study protocol.  
6.1. Study Interventions Administered   
Intervention 
Name  Tirzepatide (LY3298176 ) Placebo  
Type  Drug  Drug  
Dose 
Formulation  Single -dose pen  Single -dose pen  
Dosage 
Level(s)  10 mg QW,  
15 mg QW  Not applicable  
Route of 
Administration  SC SC 
Use Experimental  Placebo  
IMP and 
NIMP  IMP IMP 
Sourcing  Provided centrally by the sponsor and dispensed via IWRS  
Packaging and 
Labeling  Study intervention  will be provided in autoinjectors (single -dose 
pens), packaged in cartons to be dispensed. Clinical study materials 
will be labeled according to country regulatory requirements  
Abbreviations: IMP = investigational medicinal product;  IWRS = interactive web -response system ; NIMP = non -
investigational medicinal product; QW = once -weekly; SC  = subcutaneous.  
There are no restrictions on the time of day each weekly dose of study intervention  is given, but 
it is advisable to administer  the SC injections on the same day and same time each week. The 
actual date , time, and injection details  of all dose administrations will be recorded in the diary by 
the participant. If a dose of study  intervention  is missed, the participant  should take it as s oon as 
possible unless it is within 72 hours of the next dose, in which case that dose should be skipped , 
and the next dose should be taken at the appropriate time. The day of weekly administration can 
be changed if necessary , as long as the last dose was administered 72 or more hours before.  
All participant s will inject study intervention  subcutaneously in the abdomen or thigh using the 
injection supplies provided; a caregiver may admini ster the injection in the participan t’s upper 
arm. A new  autoinjector will be used for each injection.  If study  intervention  is to always be 
injected in the same body region, participants  should be advised to alternate  injection site s each 
week.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 39 6.1.1.  Medical Devices   
The combination products  provided for use in the study are tirzepatide  autoinjector (or matching 
placebo) . Any medical -device incidents, including those resulting from malfunctions of the 
device, must be detected, documented, and reported by the investigator throughout the study ( see 
Section  10.3). 
6.2. Preparation , Handling , Storage , and Accountability   
 The investigator or designee must confirm appropriate storage  conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study  intervention.  
 Only participants enrolled in the study may receive study intervention . Only authorized 
study personnel  may supply  study intervention. All study intervention must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized  study personnel . 
 The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is , receipt, reconciliation, and 
final disposition records).  
 Further guidance and information for the final disposition of unused study interventions 
are in the provided instructions . 
6.3. Measures to Minimize Bias: Randomization an d Blinding   
All participants will be centrally randomly  assigned to study intervention using an IWRS. Before 
the study is initiated, the log in information and directions for the IWRS will be provided to each 
site. 
Study intervention will be dispensed at the study visits summarized in SoA.  
Returned study intervention should not be re -dispensed to the participants.  
This is a double -blind study in which participants  and study personn el, are blinded to study 
intervention. The IWRS will be programmed with blind -breaking instructions. In case of an 
emergency, the investigator has the sole responsibility for determining if unblinding of a 
participants’ intervention  assignment is warranted . Participant safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor prior to unblinding a 
participant’s intervention  assignment unless this could delay emergency treatment for the 
participant. If a participant’s intervention  assignment is unblinded, the sponsor must be notified 
immediately  within 24  hours of this occurrence . The date and reason that the blind was  broken 
must be recorded.  
If an investigator , site personnel performing assessments, or participant is unblinded, the 
participant must be discontinued from the study. In cases where there are ethical reasons to have 
the participant remain in the study, the  investigator must obtain specific approval from a sponsor 
clinical research physician (CRP) for the  participant to continue in the study.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 40 Stratification  
Participants  will be stratified at randomization  per ISA  by country/geographic region, baseline 
AHI (m oderate/severe), and gender.  
6.4. Study Intervention Compliance   
A record of the number of single -dose pens dispensed to and taken by each participant must be 
maintained and reconciled  with study intervention and compliance records. Intervention start and 
stop dates, including dates for intervention delays and/or dose reductions will also be recorded.  
Treatment compliance for each visit interval is defined as taking at least 75% of the required 
doses of study intervention . Similarly, a participant will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of medication (more than 125%) . 
Participants considered to be poorly compliant with their medication and/or the study procedures 
will receive additional training and instruction, as required, and will be reminded of the 
importance of complying with the protocol.  
6.5. Dose Modification   
Dose modification  is permitted for management of intolerable GI symptoms  during the first 24 
weeks of the treatment period  (Section 6.5.1 ). 
Participants who do not tolerate at least  10 mg even after the described measures, including 1 de-
escalation and re -escalation attempt, will be discontinued  from the study intervention  but remain 
in the study for continued follow -up. 
Interventions to optimize study intervention  tolerance and adherence may be employed 
throughout the study and include, but are not limited to, brief temporary interruptions  
(Section  7.1.2 ) and use of additional medications  to manage GI symptoms (for example, nausea, 
vomiting, and diarrhea).  
6.5.1.  Management of Participants with Gastroin testinal Symptoms   
In participants who experience intolerable GI symptoms (for example, nausea, vomiting, or 
diarrhea) at any time during the study, the following measures are rec ommended:  
 counselling on dietary behaviors that may help mitigate nausea and vomiting, (for 
example, eating smaller meals, splitting 3 daily meals into 4 or more smaller ones, and 
stopping eating when they feel full).  
 if symptoms persist despite #1, prescr ibing symptomatic medication (for example, 
antiemetic or antidiarrheal medication), at the investigator’s discretion . 
 if symptoms persist despite #1 and #2, interrupting study intervention  for 1 dose, 
provided the participant has taken the last 3 weekly do ses. Study treatment should be 
resumed at the assigned dose immediately, either alone or in combination with 
symptomatic medication, which can also be utilized to manage symptoms (Section 6.8). 
During the first 24 weeks of the treatment period (20 -week dose escalation plus 4 weeks), 
participants unable to tolerate 2.5 mg or 5 mg (despite the interventions mentioned  above ) will 
be discontinued from the study intervention  but remain in the study.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 41 For participants unable to tolerate any dose between 7.5 mg and 15 mg inclusive, despite the 
above measures, the investigator should contact Lilly to consider a dose de -escalation step with 
subsequent re -escalat ion by 2.5 mg every 4 weeks in a blinded fashion, to reach either the 10 -mg 
or 15 -mg dose as described below.  
Only 1 cycle of dose de -escalation and re -escalation is permitted during the first 24 weeks of the 
treatment period. MTD  is either 10 mg or 15 mg . Dose modifications after the first 24 weeks of 
the treatment period are not permitted. For temporary study treatment discontinuation , see 
Section 7.1.2 . 
Participants who tolerate  
 10 mg, but do not tolerate 12.5 mg or 15 mg even following the above measures, 
including 1 de-escalation and re -escalation attempt, will continue on 10 mg as their MTD 
dose.  
 12.5 mg, but do not tolerate 15 mg even after the above measures, including 1 de-
escalation and re -escalation attempt, will continue on 10 mg as their MTD dose.  
 15 mg will continue on 15 mg as their MTD dose.  
6.6. Continued Access to Study Intervention after the End of the Study   
Tirzepatide  will not be made available to participants after conclusion of the study . 
6.7. Treatment of Overdose   
Study  intervention overdose ( more  than the specified number of injections  in less than 72 hours ) 
will be reported  as an AE . 
In the event of an overdose, the treating physician should:  
● Contact the medical monitor immediately.  
● Evaluate the participant to determine, in consultation with the medical monitor, 
whether study intervention should be interrupted or whether the dose should be 
reduced.  
● Closely monitor the participant for any AE/SAE and laboratory abnormalities 
until study intervention  no longer has a clinical e ffect. 
6.8. Concomitant Therapy   
Participants will be permitted to use concomitant medications that they require during the study, 
except certain medications ( Section 6.8.2 ) that may interfere with the assessment of efficacy and 
safety characteristics of the study treatments.  
Investigative -site staff will inform participants that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medications during the study. This 
may not be possible when initiated for treatment of medical emergencies, in which case, the 
participant will inform t he investigator or a designated site staff member as soon as possible.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 42 Nonstudy medications taken by participants who are screened but not randomly assigned  to 
study intervention  will not be reported to Lilly unless an SAE or AE occurs that the investigato r 
believes may have been caused by a study procedure.  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements , or other specific categories of interest) that the participant is 
receiving at the t ime of screening  or receives during the study must be recorded along with:  
● Reason for use  
● Dates of administration including start and end dates  
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior  therapy.  
6.8.1.  Management of Incident Diabetes   
Incident  diabetes is defined  when any 1 of the following occur after randomization (American 
Diabetes  Association 20 20): 
 unequivocal hyperglycemia (random glucose ≥200  mg/dL) with signs or symptoms of 
hyperglycemia  
 within a 4 -week  period, any 2 of the following criteria are observed or 1 abnormal 
value  is observed and  confirmed:  
 HbA1c ≥6.5%  (48 mm ol/mol)  
 FG or 0 -hour serum glucose from 2 -hour OGT T ≥126 mg/dL (7.0 mmol/L)  
 2-hour glucose  ≥200  mg/dL (11.1  mmol/L) by a 2 -hour OGTT  
 initiation of any medication for the treatment of diabetes  
Participants  who develop type 2 diabetes during the study will be  
 provided with and trained to use a glucometer  
 educated on the signs and symptoms of hypoglycemia and its treatment  (see Section 
10.3.7.1 ), and  
 provided a diary to record hypoglycemic episodes per  Section 10.3.7.1 . 
Participants will be referred to their usual care provider and provided with a letter showing the 
study  results indicative of diabe tes. The decision to further evaluate, to initiate 
antihyperglycemic therapy, and the choice of antihyperglycemic medication will be at the 
discretion of the participant’s usual care provider, with the exception of use of DPP -4 inhibitors 
and open -label GL P-1R agonists, which are prohibited in the study  (Section 6.8.2 ). Monitoring 
for hypoglycemia includes capture of events as defined in Section 10.3 (Appendix 3). Date of 
diabetes diagnosis will be captured in the AE CRF.  
Initiation  of metformin for the treatment of diabetes is permitted, bu t metformin should not be 
initiated during the study for the treatment of other metabolic conditions (for example, polycystic 
ovary syndrome  and diabetes prevention).  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 43 6.8.2.  Prohibited Concomitant Medications   
The following medications are prohibited during the study:  
 DPP-4 inhibitors  
 Open -label GLP -1R agonists  
 Stimulants (for example , modafinil, armodafinil, solriamfetol, pitolisant, amphetamine, 
dextroamphetamine, dexmethylphenidate, methylphenidate, and lisdexamfetamine)  
 medications that may cause significant weight gain (such as, but not limited to, 
paroxetine , tricyclic antidepres sants, atypical antipsychotic and mood stabilizers ). 
 Medications that may cause weight loss (such as, but not limited to, liraglutide,  
semaglutide,  orlistat, sibutramine, phe nylpropanolamine, mazindol, phentermine, 
lorcaserin, naltrexone/bupropion , phenter mine/topiramate combination , pramlintide,  
zonisamide,  and topiramate)  
 OTC, herbal, or supplemental medications that, in the opinion of the investigator, may 
interfere with the study  
 hypnotics, mirtazapine, opioids, trazodone , pramlintide , sibutramine, orlistat, and 
zonisamide  
 Systemic glucocorticoid  therapy , per discussion with sponsor  
 Use of any over-the-counter  or prescription medications that could affect the evaluation 
of excessive sleepiness , per investigator discretion  (such as, but  not limited to, CBD oil, 
THC, etc .) 
 Any glucose -lowering medication, including metformin  
In addition,  
 Active device treatment of OSA other than PAP therapy (for example, dental appliance), 
or other treatment that, in the opinion of the investigator, may interfere with study 
outcomes.  
Participants who initiate and will not or cannot discontinue a prohibited medication , device, or 
other treatment  will be permanently discontinued from study intervention per Section 7.1. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 44 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal   
Discontinuation of specif ic sites or of the study as a whole are handled as part of Section 10.1, 
Appendix 1.  
7.1. Discontinuation of Study Intervention   
When necessary, a participant may be permanently discontinued from study intervention. If so, 
the participant will remain in the study and follow procedures for remaining study visits, as 
shown in the SoA.  
A participant who prematurely discontinues study intervention is strongly encouraged to remain 
in the study for safety and efficacy assessment s through the treatment period and post -treatment 
follow -up. 
If a participant who dis continues the double -blind study treatment prematurely declines  to 
complete the remaining scheduled study visits, then the participant should  complete the early ED 
procedures  indicated in the SoA. Participants should  be encouraged to come back for the last 
treatment visit (Visit 11)  to complete the end -of-treatment phase procedures  and return for the 
post-treatment follow -up Visit 801.  
Possible reasons leading to permanent disco ntinuation of study intervention : 
 participant  decision  
o the participant requests to discontinue study intervention  
 clinical considerations  
o initiation of  a prohibited medication (Section 6.8.2 ), if participants will not or 
cannot discontinue them  
o BMI ≤18.5  kg/m 2 is reached at any time during the treatment period , study 
intervention discontinuation should be considered   
o TEAE 
▪ intolerable GI symptoms despite management (Section 6.5.1 )  
Note:  The investigator should contact the Sponsor CRP to discuss 
whether it is medically appropriate for the participant to continue study 
treatment.  
▪ significant elevation of calcitonin  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 45 ▪ If the investigator determines that a systemic hypersensitivity reaction 
has occurred related to study intervention administration, the 
participant may be permanently discontinued from the study 
intervention, and the sponsor’s designated medical monitor shoul d be 
notified. If the investigator is uncertain about whether a systemic 
hypersensitivity reaction has occurred and whether discontinuation of 
study intervention is warranted, the investigator may consult the 
sponsor  
▪ occurrence of any other TEAE, SAE, or c linically significant finding 
for which the investigator believes that permanent study  intervention  
discontinuation is the appropriate measure to be taken  
o Diagnosis  of 
▪ T1DM  
▪ Thyroid C -cell hyperplasia, MTC or MEN Syndrome type 2 after 
randomization  
▪ acute or  chronic pancreatitis  
▪ an active or untreated malignancy (other than basal or squamous cell 
skin cancer, in situ  carcinomas of the cervix, or in situ  prostate cancer) 
after randomization  
o onset of pregnancy in a female participant (see Section s 7.2 and 8.3.2 ) 
o Suicidal Ideation and Behavior  
▪ PHQ -9 score ≥15  
 Participants should be refer red to a Mental Health Professional 
(MHP)  to assist in deciding whether the participant  should be 
discontinued from study intervention . If a participant’s 
psychiatric disorder can be adequately treated with psycho - 
and/or pharmacotherapy, then the particip ant, at the discretion 
of the Investigator (in agreement with the MHP), may be 
continued in the trial on randomly assigned  therapy.  
▪ in addition, study intervention  may be discontinued if participants:  
 answered “yes” to Question 4 or Question 5 on the “Suicidal 
Ideation ” portion of the C -SSRS, or 
 answered “yes” to any of the suicide -related behaviors on the 
Suicidal Behavior portion of the C -SSRS.  
A psychiatrist or appropriately trained professional may assist in the decision to discontinue the 
participa nt. The participant should be referred to a MHP for further evaluation and care.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 46 7.1.1.  Liver Chemistry Stopping Criteria   
The study intervention  should be interrupted or discontinued if  one or more of these conditions 
occur:  
Elevation  Exception  
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than 2 weeks   
ALT or AST >3x ULN and either TBL >2x ULN or INR >1.5  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should  be used 
for drug interruption/ discontinuation 
decisions rather than TBL>2x ULN.  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN, when the source of increased ALP is the liver   
ALP >2.5x ULN and TBL > 2x ULN  In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for drug interruption/ discontinuation 
decisions rather than TBL>2x ULN.  
ALP >2.5x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Source: FDA 2009 and other consensus guidelines, with minor modifications  
Abbreviations: ALT = alanine aminotransferase ; AST = aspartate aminotransferase; ALP = alkaline phosphatase ; 
INR = international normalized ratio; TBL = total bilirubin  level ; ULN = upper limit of normal.  
Resumption of the study intervention  can be considered only in consultation with the 
Lilly -desig nated medical monitor and only if the liver test results return to baseline and if a 
self-limited non -drug etiology is identified.  
Participants who are discontinued from study intervention due to a hepatic event or liver test 
abnormality should have additi onal hepatic safety data collected as described in Section 10.6, 
Appendix 6. 
7.1.2.  Temporary Discontinuation   
In certain situations, after randomization, the investigator may need to temporarily interrupt 
study intervention . Every effort should be made by the investigator to maintain pa rticipants on 
study intervention  and to restart study intervention  after any temporary interruption, as soon as it 
is safe to do so. Distribution of study intervention  at the correct dose will be per IWRS 
instructions.  
Investigators should inform the spons or that study intervention  has been temporarily interrupted. 
The data related to temporary interruption of study treatment will be documented in source 
documents and entered on the CRF.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 47 If study 
intervention  
interruption is…  then…  
2 consecutive doses 
or less  participant restarts study intervention  at last 
administered dose, as per escalation 
schedule.  
3 consecutive doses 
or more  participant restarts study intervention  (at 5 
mg, managed by IWRS) and repeats dose 
escalation scheme.  
Due to an AE  the event is to be documented and followed 
according to the procedures in Section 8.3 
of this protocol.  
Due to intolerable 
persistent GI AE  participants  should be treated as suggested 
in Section 6.5.1 . 
Abbreviations: AE = adverse event; GI = gastrointestinal; IWRS = interactive web -respo nse system . 
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant may withdraw from the study:  
 at any time at the participant’s own request  
 at the request of the participant’s designee (for example, parents or legal guardian)  
 a participant will be withdrawn from the study in case of inadvertent enrollment  
 at the discretion of the investigator for safety, behavioral, compliance, or administrative 
reasons  
o If the participant becomes pregnant during the study (see Section 8.3.2  for 
additional details)  
 if enrolled in a ny other clinical study involving an investigational product, or enrolled in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study  
 if the participant, for any reason, requires treatment with a therapeuti c agent that is 
prohibited by the protocol and has been demonstrated to be effective for treatment of the 
study indication. In this case, discontinuation from the study occurs prior to introduction 
of the new agent.  
At the time of discontinuing from the st udy, if possible, the participant will complete procedures 
for an ED visit and post-treatment follow -up, if applicable , as shown in the SoA. If the 
participant has not already discontinued the study intervention, the participant will be 
permanently discont inued from the study intervention at the time of the decision to discontinue 
the study.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of con sent. If a participant 
withdraws from the study, the participant may request destruction of any samples taken and not 
tested, and the investigator must document this in the site study records.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 48 7.3. Lost to Follow  up  
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. Site personnel or designee are 
expected to make diligent attempts to contact participants who fail to return for a scheduled visit 
or were otherwise unable to be followed up by the site.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 49 8. Study Assessments and Procedures   
Study procedure s and their timing are summarized in the SoA.  
Immediate  safety concerns  should be discussed with the s ponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention . 
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that  potential participant s 
meet all eligibility criteria. The investigator will mai ntain a screening log to record details of all 
participant s screened and to confirm eligibility or record reasons for sc reening failure, as 
applicable.  
8.1. Efficacy Assessments   
8.1.1.  Primary Efficacy Assessment   
8.1.1.1.  Polysomnography   
The primary efficacy assessment in this study is AHI. AH I measurements will be collected via 
polysomnography.  
Polysomnography assessments (including AHI, blood oxygen saturation parameters, PR, sleep 
parameters) will be performed during 1 -night, overnight clinic stays , per the SoA . Data from the 
PSGs will be re ad and scored centrally  using the AASM  1B hypopnea scoring method (when 
there is ≥4% oxygen desaturation from pre -event baseline ; see Section 10.10 , Appendix 10  for 
definitions ) (Hamilton et al. 2021).  
The eligibility criteria and AHI related endpoints of the study will be assessed based on central 
reading of the PSG.  
8.1.2.  Secondary Efficacy Assessments   
8.1.2.1.  Patient -Reported Outcomes   
8.1.2.1.1.  Functional Outcomes of Sleep Questionnaire (FOSQ)   
The FOSQ will be included to assess change in FOSQ domains and total score from baseline to 
Week 52. The FOSQ is a 30 -item sleep -specific, participant -completed questionnaire used to 
assess the effect of disorders associated with  excessive daytime sleepiness  (EDS ) on daily 
functioning in adults. It assesses  the following 5 domains of  
 General productivity (8 items)  
 Activity level (9 items)  
 Vigilance (7 items)  
 Social outcomes (2 items)  
 Intimate and sexual  relationships (4 items)  
The FOSQ items assess participant ’s current status with each item rated on a scale of 1 (extreme 
difficulty) to 4 (no difficulty), with an additional not applicable (0 = “I don’t do this activity for 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 50 other reasons”) also available.  Individual domain scores are calculated by taking the mean of 
answered, non -zero items within each domain and a total score can be calculated by first 
computing the mean score for each domain, then multiplying the mean of the domain scores by 5 
(Weaver et  al. 1997). The total score for the FOSQ 10 -item short form (FOSQ -10) can also be 
calculated.  
8.1.2.1.2.  PROMIS Short Form v1.0 Sleep -related Impairment 8a   
The PROMIS Short Form v1.0 Sleep -related Impairment 8a  assesses  self-reported perceptions of 
alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional 
impairments associated with sleep problems or impaired alertness . The PROMIS Short Form 
v1.0 Sleep -related Impairment 8a  consists of 8 items each  rated on a 5 -point scale ranging from 
“not at all ” to “very much .” Items have a recall  period of “in the past 7 days. ” Individual item 
scores are totaled to obtain a raw score, with higher  scores indicating more sleep-related 
impairment . Raw scores can be converted to a T -score, which is  standardized with a mean of 50 
and a SD of 10.  (Northwestern, 2016a)  
8.1.2.1.3.  PROMIS Short Form v1.0 Sleep Disturbance 8b   
The PROMIS Short Form v1.0 Sleep Disturbance 8b assesses self -reported perceptions of sleep 
quality , sleep depth, and restoration associated with sleep, including perceived diffic ulties and 
concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and 
satisfaction with sleep. The PROMIS Short Form v1.0 Sleep Disturbance 8b consists of 8 items 
each rated on a 5 -point scale ranging from “not at all ” to “very much, ” “never” to “always,” or 
“very poor” to “very good.” Items have a recall period of “in the past 7 days. ” Individual item 
scores are totaled to obtain a raw score, with higher scores indicating more sleep disturbance. 
Raw scores can be conve rted to a T -score, which is standardized with a mean of 50 and a SD of 
10. (Northwestern, 2016b)  
8.1.2.1.4.  Epworth Sleepiness Scale   
The ESS will be included to assess improvements in exces sive daytime sleepiness from baseline 
to Week 52 . The ESS is an 8 -item participant -completed measure that asks the participant to rate 
on a scale of 0 (would never doze) to 3 (high chance of dozing), their usual chances of dozing in 
8 different daytime sit uations, with a recall period of “in recent times.” The ESS total score is the 
sum of the 8 -item scores and ranges from 0 to 24, with higher scores indicating greater daytime 
sleepiness ( Johns  1991).  
8.1.2.1.5.  Short -Form 36 Version 2 Health Survey, Acute Form, 1 -week Recall Version   
The SF -36v2  will be included to assess health -related quality of life from baseline to Week 52. 
The SF -36v2 acute form, 1 -week recall version is a 36 -item gener ic, participant -completed 
measure designed to assess the following 8 domains over “the past week.”  
 Physical functioning  
 Role -physical  
 Bodily pain  
 General health  
 Vitality  
 Social functioning  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 51  Role -emotional, and  
 Mental health  
The Physical Functioning domain assesses limitations due to health “now” while the remaining 
domains assess functioning “in the past week.” Each domain is scored individually and 
information  from these 8 domains are further aggregated into 2 health compone nt summary 
scores: Physical Component Summary and Mental Component Summary. Items are answered on 
Likert scales of varying lengths (3 -point, 5 -point, or 6 -point scales). Scoring of each domain and 
both summary scores are norm based and presented in the for m of T -scores, with a mean of 50 
and SD of 10; higher scores indicate better levels of function and/or better health (Maruish 
2011).  
8.1.2.1.6.  Patient Global Impression of Status – Obstructive Sleep Apnea (PGIS -OSA) 
Symptoms Scales   
Three  patient global impression of status scales will be included to assess categorical shift in 
participant self -rated assessment of their OSA symptom severity  from baseline to Week 52. 
PGIS -OSA Fatigue  
This is a single -item, participant self -rated assessment of their overall level of fatigue due to 
OSA, “ over the past 7 days .” The item is rated on a 4-point scale ranging from “ No fatigue” to 
“Severe  fatigue.”  
PGIS -OSA Sleepiness  
This is a single -item, participant self -rated assessment of their overall level of sleepiness due to 
OSA  during waking hours , “over the past 7 days .” The item is rated on a 4-point scale ranging 
from “Not at all sleepy” to “ Very  sleepy.”  
PGIS -OSA Snoring  
The PGIS -OSA Snoring sca le consists of two items. The first item is a participant self -rated 
assessment  of their overall perception of the severity of their snoring due to OSA, “ over the past 
7 days ,” with respect to how much  their snoring has affected their sleep . The item is ra ted on a 4-
point scale ranging from “ Not at all affected ” to “Very affected .” For the second item , 
participants will be asked on a 3 -point scale (“Not at all” to “All the time” ) if they have ever 
been told by someone else that they snore in their sleep.  
8.1.3.  Exploratory Efficacy Assessments   
8.1.3.1.  Actigraphy   
The actigraphy device (AX6) will be utilized in the OSA trial to objectively evaluate the effect of 
tirzepatide on various sleep and physical activity parameters including but not limited to change 
of daytime  sleep time, sleep efficiency, and change in daytime physical activity from baseline. 
The actigraphy dev ice is a data logger capable of recording raw data from a suite of integrated 
sensors and can be configured to collect movement -relevant data in an uninterrupted fashion for 
up to 2 months, thus is ideal for collecting longitudinal movement data ( for examp le, physical 
activity, sleep, etc.) in real -world health research and well -defined clinical trials. The actigraphy 
device meets the CE (Conformite Europeenne ) mark requirements. Participants should wear the 
actigraphy device for 7 consecutive days , 5 times  during the study,  per the SoA . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 52 Lack of participation in actigraphy collections at any time is not considered a protocol deviation.  
8.1.3.2.  Patient Global Impression of Change – Obstructive Sleep Apnea (PGIC -OSA)  
Symptoms Scales   
Four patient global impression of change scales will be included to assess categorical shift in 
participant self -rated assessment of change in their OSA symptom severity from baseline to 
Week 52. 
PGIC-OSA Fatigue  
This is a single -item, participant self -rated assessment of the  change in their  overall level of 
fatigue due to OSA, “ since you started taking the study medication .” The item is rated on a 5 -
point scale ranging from “ Much worse ” to “ Much better .” 
PGIC-OSA Sleepiness  
This is a single -item, participant self -rated assessment of the change in their overall level of 
sleepiness due to OSA  during waking hours , “since you started taking the study medication .” 
The item is rated on a 5 -point scale ranging from “ Much more sleepy ” to “ Much less sleepy .” 
PGIC-OSA Sleep  Quality  
This is a single -item, participant self -rated assessment of the change in their overall sleep quality  
due to OSA, “ since you started taking the study medication .” The item is rated on a 5 -point scale 
ranging from “ Much worse ” to “ Much better .” 
PGIC-OSA Snoring  
This is a single -item, participant self -rated assessment of the overall change in how their snoring 
has affected their sleep , “since you started taking  the study medication .” The item is ra ted on a 5 -
point scale ranging from “ My sleep is much more affected ” to “ My sleep is much less affected .” 
8.1.3.3.  EQ-5D-5L  
The EQ -5D-5L (EuroQol  Research Foundation 2019) is a standardized 5 -item self -administered 
instrument for use as a measure of health outcome. It provides a simple descriptive profile and a 
single index value for health status that can be used in the clinical and economic evaluation of 
health care as well as population health surveys. The EQ -5D-5L assesses 5 dimensions of health:  
 mobility  
 selfcare  
 usual activities  
 pain/discomfort, and  
 anxiety/depression.  
The 5L version, scores each dimension at 5 levels:  
 no problems  
 slight problems  
 moderate problems  
 severe pro blems, and  
 unable to perform/extreme problems.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 53 A total of 3125 health states is possible. In addition to the health profile, a single health state 
index value can be derived based on a formula that attaches weights to each of the levels in each 
dimension. This index value ranges between less than 0 (where 0 is a health state equivalent to 
death; negative values are  valued as worse than dead) to 1 (perfect health). In addition, the EQ 
Visual Analog Scale records the respondent’s self -rated health status on a  vertical graduated (0 to 
100) visual analog scale.  The participant rates his/her perceived health from 0 (the worst 
imaginable health) to 100 (the best imaginable health ). In conjunction with the health state data, 
it provides a composite picture of the r espondent’s health status.  
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations   
A complete physical examination will include, at a minimum, assessments of the CV, 
respiratory, gastrointestinal and neurological  systems  as well as a thyroid exam ination . Height , 
weight , and waist circumference  will also be measured and recorded.  
A symptom -directed physical assessment  will be performed as indicated in the SoA, as clinically 
indicated.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
8.2.2.  Vital Signs   
For each  participant , vital s igns measurements should be conducted according to the SoA 
(Section  1.3). 
8.2.3.  Electrocardiograms  (ECG)   
Single  12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals.  
A local single 12 -lead ECG will be collected at designated visits. ECGs should be collected prior 
to collection of blood samples for laboratory testing, including PK samples. Participants should 
be supine for at least  5 minutes before ECG collections and remain supine but awake during the 
ECG collection. ECGs may be repeated at the investigator’s discretion at any visit.  
After enrollment, if a clinically significant increase in the QT/QTc interval from baseline or 
other clinically significant quantitative or qualitative change from baseline is identified, the 
participant will be assessed by the investigator for symptoms (for example, palpitations, near 
syncope, and syncope) and to determine whether the participant can continue in the study. The 
investigator or qualified designee is responsible f or determining if any change in participant 
management is needed and must document his/her review of the ECG printed at the time of 
evaluation from at least 1 of the replicate ECGs from each time point.  
8.2.4.  Clinical Safety Laboratory Tests   
See Section 10.2, Appendix 2  for the list of clinical laboratory tests to be performed and the So A 
for the timing and frequency.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 54 The investigator must review the laboratory results , document this review, and report  any 
clinically relevant changes occurring during the study as an AE . The laboratory results must be 
retained with source documents unless a Source Documen t Agreement or comparable document 
cites an electronic location that accommodates the expected retention duration. Clinically 
significant abnormal laboratory findings are those which are not associated with the underlying 
disease, un less judged by the investigator to be more severe than expected for the participant ’s 
condition.  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study  should be repeated until the values return to n ormal or baseline or are no longer 
considered clinically significant by the investigator or medical monitor.  
 If such values do not return to normal/baseline within a period of time judged reasonable 
by the investigator, the etiology should be identified an d the sponsor notified.  
 All protocol -required laboratory assessments, as defined in  Section 10.2, Appendix 2 
must be conducted in accordance with the SoA, standard collection requirements , and 
laboratory manual . 
If laboratory values from non -protocol specified laboratory assessments performed at an 
investigator -designated local laboratory require a change in participant management or are 
considered cli nically significant by the investigator ( for example , SAE or AE or dose 
modification), then  report the information as an AE . 
8.2.5.  Pregnancy Testing   
See the SoA (Section 1.3) for testing for pregnancy and timepoints.  
See Appendix 4 (Section 10.4) for additional information for pregnancy.  
8.2.6.  Suicidal Ideation and Behavior Risk Monitoring   
Patients with obesity may occasionally develop suicidal ideation or behavior.  
Participants  should be monitored appropriately and observed closely for SIB or any other 
unusual changes in behavior, especially at the beginning and end of the course of intervention , or 
at the time of dose changes, either i ncreases or decreases. Participants who experience signs of 
SIB should undergo a risk assessment. All factors contributing to SIB should be evaluated and 
consideration should be given to discontinuation of the study intervention . 
Baseline assessment of sui cidal ideation and behavior/intervention emergent suicidal ideation 
and behavior  will be monitored using the C -SSRS  and PHQ -9. 
8.2.6.1.  C-SSRS   
Columbia Suicide -Severity Rating Scale (C -SSRS) is a scale that captures the occurrence, 
severity , and frequency of suicidal ideation and behavior  during the assessment period  via a 
questionnaire . The scale  was developed by the National Institute of Mental Health ( NIMH ) trial 
group (TASA) for the pu rpose of being counterpart to the Columbia Classification Algorithm of 
Suicide Assessment (C -CASA)  categorization of suicidal events . (The Columbia Lighthouse 
Project, 2013)  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 55 For this study, the C -SSRS is a dapted  for the assessment of the ideation and behavior categories 
only. The Intensity of Ideation and Lethality of Behavior sections are removed . 
8.2.6.2.  PHQ -9  
The PHQ -9 is a validated self -report screening tool that assesses the presence and intensity of 
depressive symptoms. The PHQ -9, which incorporates the 9 Diagnostic and Statistical Manual -
IV depression criteria as “0” (not at all) to “3” (nearly every day), was developed for use in 
primar y care settings (Kroenke et al. 2001).  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints   
The definitions of the following events can be found in Section 10.3, Appendix 3:  
 AEs 
 SAEs  
 PCs 
These events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the se definition s and remain responsible for following up events that 
are serious, considered related to the  study intervention or study procedures, or that caused the 
participant to discontinue the study intervention before completing the study  (see Section 7). 
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs and AEs of special interest (as defined in Section 8.3.3 ) will 
be followed until resolution, stabilization, the event is otherwise explained, or the participant is 
lost to follow -up (as defined in Section 7.3). For PCs, the investigator is responsible for ensuring 
that follow -up includes any supplemental investigations as indicated to elucidate the nature 
and/or causality.  Further information on follow -up procedure s is provided in  Section  10.3, 
Appendix  3. 
8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for  
Reporting  Back -Up 
Method of 
Reporting  
AE 
AE Signing of 
the ICF  participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 56 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for  
Reporting  Back -Up 
Method of 
Reporting  
SAE  
SAE and SAE 
updates – prior 
to start of study 
intervention and 
deemed 
reasonably 
possibly related 
to study 
procedures  Signing of 
the ICF  start of 
intervention  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAE  and SAE 
updates  – after 
start of study 
intervention  Start of 
intervention  participation 
in study has 
ended  Within 24 hours of 
awareness  SAE CRF  SAE paper 
form  
SAEa – after 
participant’s 
study 
participation has 
ended and the 
investigator 
becomes aware  After 
participant’s 
study 
participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy  
Pregnancy in 
female 
participants and 
female partners 
of male 
participants  After the 
start of study 
intervention  until 1 month 
after the last 
dose of study 
intervention  Within 24 hours (see 
Section 8.3.2 ) Pregnancy paper 
form  Pregnancy 
paper form  
PCs 
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 57 Event  Collection 
Start  Collection 
Stop  Timing for Reporting 
to Sponsor or 
Designee  Mechanism for  
Reporting  Back -Up 
Method of 
Reporting  
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  — — As soon as possible 
upon site awareness  Originally 
completed PC form 
with all changes 
signed and dated by 
the investigator  N/A 
PC (if 
investigator 
becomes aware)  Participation 
in study has 
ended  N/A Promptly  PC form   
Abbreviations: AE = adverse event; CRF = case report form; ICF = informed consent form; N/A = not applicable; 
PC = product complaint; SAE = serious adverse event . 
a Serious adverse events  should not be reported unless the investigator deems them to be possibly related to study 
treatment  or study participation . 
8.3.1.1.  Adverse Event Monitoring with a Systematic Questionnaire   
Nonleading AE collection  should occur prior to the collection of the C -SSRS  and PHQ -9, if AE 
and C -SSRS/PHQ -9 collections done on the same day . 
If a suicide -related  event is discovered during the C -SSRS  or PHQ -9 but was not captured during 
the nonleading AE collection, sites should not change the AE form.  
If an AE is serious  or leads to discontinuation, it needs to be  included on the AE form and the 
process for repor ting SAEs is followed . 
8.3.2.  Pregnancy   
Collection of pregnancy information  
Male participants with partners who become pregnant  
 The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive study intervention . 
 After learning of a pregnancy in the female partner of a study participant, the investigator 
will 
o obtain a consent  to release information  from the pregnant female partner 
directly, and 
o within 24 hours after obtaining this consent will record pregnancy information 
on the appropriate form and submit it to the sponsor . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 58  The female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the sponsor. 
Generally, the follow -up will be no longe r than 6 to 8  weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of  gestational 
age, fetal status (presence or absence of anomalies) or indication for the procedure.  
Female participants who become preg nant 
 The investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial i nformation will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours  of 
learning of a participant ’s pregnancy.  
 The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Gene rally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported , regardless of gestational age,  fetal status (presence or absence 
of anomalies) or indication for the procedure.  
 While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
 A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occurring 
at ≥20 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
 Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by the investigator will be reported to the  sponsor as described in protocol 
Section  8.3.1 . While the investigator is not obligated to actively seek this information in 
former study participant s, he or she may learn of an SAE through spontaneous reporting.  
 Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention and be withdrawn from the study. If the participant is 
discontinued from the st udy, follow the standard discontinuation process and continue 
directly to the study follow -up phase. The follow -up on the pregnancy outcome should 
continue independent of intervention or study discontinuation.  
8.3.3.  Adverse Events of Special Interest   
Adverse  events of special interest are prospectively defined to include  
 severe hypoglycemia  
 MACE  (adjudicated) ; includes, but not limited to CV death, nonfatal MI, nonfatal stroke,  
hospitalization for unstable angina, and hospitalization for heart failure  
 treatment -emergent  arrhythmias and cardiac conduction disorders  
 hepatobiliary disorders ; includes biliary colic, cholecysti tis, and other gallbladder disease  
 severe GI events  
 acute renal events  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 59  Major Depressive Disorder/suicidal behavior and i deation  
 pancreatitis  (adjudicated)  
 c-cell hyperplasia and thyroid mali gnancies  
 allergic/ hypersensitivity reactions ; includes ISRs  and ADA  formation  
If these events are reported, investigators may be prompted to collect additional data about the 
event.  Sections 10.1.5.1  and 10.1.5.2  (Appendix 1), outline additional information on CV and 
pancreatic adjudi cation. Section 10.3.7  (Appendix 3) outline additional information on 
hypoglycemia, hypersensitivity reactions , and ISRs . 
8.4. Pharmacokinetics   
Blood samples will be obtained from all participants enrolled in the 2 ISAs to enable the 
characterization of tirzepatide PK and exposure response relationships, as permissible.  Samples 
will be collected with concurrent immunogenicity samples at timepoints indicated in the SoA 
(Section  1.3). 
Blood  samples collected from participant s in the placebo arms will not be included in the 
bioanalyses of drug concentrations.  
 Plasma  samples will be collected for measurement of plasma  concentrations of 
tirzepatide  as specified in the SoA  
 Instructions for the collection and handling of biological samples will be provided by the 
sponsor. The actual date and time (24 -hour clock time) of each sample will be recorded.  
Drug concentration information that may unblind the study will not be reported to investigative 
sites or blinded  personnel . 
8.4.1.  Bioanalytical Methods   
Samples will be analyzed at a laboratory approved by the sponsor , and stored at a facility  
designated  by the sponsor. Concentrations of tirzepatide  will be a ssayed using a validated liquid 
chromatography mass spectrometry method. Analyses of samples collected from placebo -treated 
participants are not planned. Bioanalytical samples collected to measure tirzepatide  
concentrations will be retained for a maximum of 1 year following last participant  visit for the 
study.  During this time, samples remaining after the bioanalyses may be used for exploratory 
analyses such as metabolism work, protein binding, and/or bioanal ytical method cross -
validation.  
8.5. Pharmacodynamics   
Samples to assess the PD properties of tirzepatide are included in the efficacy measures and not 
applicable  in this section.  
8.6. Gene tics  
A whole blood sample will be collected for pharmacogenetic analysis where local regulations 
allow.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 60 8.7. Biomarkers   
Blood  samples will be collected to address questions of relevance to drug disposition, target 
engagement , PD, mechanism of action, variability of study participant response (including 
safety), and clinical outcome.  Biomarkers will include measurement of biomolecules  including 
proteins, lipids, and other cellular elements.  
Samples will be collected according to the schedule described in the SoA and as detailed in the 
laboratory  manual provided separately to sites . 
All samples  will be coded w ith the study participant number. These samples and any data 
generated can be linked back to the study participant only by the investigator site personnel.  
Lilly  may store samples after the end of the study to achieve study objectives. Additionally, with 
participant ’s consent, samples may be used for further research by Lilly or others such as 
universities or other companies to contribute to the understanding of OSA, obesity , or other 
diseases , the development of related or new treatments, or research methods.   
See Section 10.1.12 , Appendix 1 for details related to sample retention.  
8.8. Immunogenicity Assessments   
At the visits and times specified in the SoA (Section 1.3), venous blood  samples will be 
collected  for analysis  to determine antibody production against  tirzepatide.  Antibodies may be 
further characterized for : cross -reactive binding to native GIP and  GLP -1, neutraliz ing activity 
of tirzepatide  on the GIP and GLP -1 receptors , and neutralizing  activity  to native GIP and/or 
GLP -1. To interpret the results of immunogenicity,  a venous blood  sample will be collected  at 
the same time points  to determine the serum  concentrations of  tirzepatide . All samples  for 
immunogenicity should be taken  predose  when applicable and  possible.  
Treatment -emergent  ADAs are defined in  Section  10.3, Appendix 3 . 
Immunogenicity  will be assessed by a validated assay designed to detect ADAs in the presence 
of tirzepatide  at a laboratory approved by the sponsor. The purpose of retention, the  maximum 
duration  of retention, and facility for long -term storage of samples is described in  Section  10.2, 
Appendix 2. Samples may also be used for development and control of an immunogenicity 
assay.  
For details related to sample retention, see Section 10.1.12 , Appendix 1 . 
8.9. Health Economic s OR Med ical Resource Utilization and Health 
Economic s  
Health  economics or medical resource utilization and health economics parameters are not 
evaluated in this study . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 61 9. Statistical Considerations   
This section is a summary of the planned statistical analyses of the most important endpoints , 
including primary and key secondary endpoints.  The SAP  will include more technical and 
detailed description of the statistical analyses described in this section.  
Unblinding details will be specified in the unblinding plan section of the SAP or in a separate 
unblinding plan document.  
9.1. Statistical Hypotheses   
For each ISA, the primary objective is to demonstrate that tirzep atide at the MTD  (10 mg or 
15 mg) is superior to Placebo in treating participants with OSA with respect to AHI endpoint. 
Thus the  null and alternative hypothes es will be defined as below.  
Null hypothesis: tirzepatide  at the MTD (10  mg or 15  mg) is not different from the placebo with 
respect to the mean percent change from baseline in AHI at 52 weeks . 
Alternative  hypothesis: tirzepat ide at the MTD (10  mg or 15  mg) is superior to the placebo with 
respect to the mean percent change from baseline in AHI at 52 weeks . 
The treatment effect will be defined as the difference between the estimates of the mean  change 
from baseline at 52 weeks  for tirzepatide  at the MTD (10  mg or 15  mg) and placebo.  
9.1.1.  Multiplicity Adjustment   
The statistical comparisons for the primary efficacy endpoint and the key secondary endpoints 
will be carried out based on  a graphical approach for multiple comparisons within each ISA  
(Bretz et al. 2011). The graphical approach is a closed testing procedure; hence, it strongly 
controls the familywise Type I error rate (2-sided alpha level of 0.05) across the primary and key 
secondary objectives (Alosh et al. 2014). Details about the graphical approach will be described 
in the SAP.  
9.2. Analyses  Sets  
This table describes the pop ulations that will be used for statistical analyses within each ISA of 
the master  protocol. Additional intervention -specific populations for analyses may be described 
in the respective ISA. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 62 Analysis Set or Population  Description  
mITT population  All randomly assigned  participant s who are exposed to at 
least 1 dose of study intervention .  
FAS  Data obtained during treatment period from the mITT 
population  excluding those discontinuing study due to 
inadvertent enrollment , regardless of adherence to study 
intervention  
EAS  Data obtained during treatment period from the mITT 
population  excluding those discontinuing study due to 
inadvertent enrollment , excluding data after 
discontinuation of study intervention  (last dose + 7 days)  
SS Data obtained  during treatment period plus safety follow -
up period from mITT population, regardless of adherence 
to study intervention  
Abbreviations: EAS = efficacy analysis set; FAS = full analysis set; mITT = modified intent -to-treat; SS = safety 
analysis set.  
9.3. Stati stical Analyses   
9.3.1.  General Considerations   
Statistical analysis will be the responsibility of the sponso r or its designee. Statistical analysis for 
each ISA will be conducted individually and a combined analysis with both ISA s is not planned.  
The SAP  will be finalized prior to the unblinding of the first ISA . 
Changes to the data analysis methods will require  an amendment only if a principal feature of the 
master protocol  is changed . Any other change to the data analysis methods, and the justification 
for making the change, will be described in the SAP  or the CSR  for each respective ISA. 
Additional exploratory  analyses of the data will be conducted as deemed appropriate.  
Efficacy analyses  will be conducted on all participant s meeting study eligibility criteria  randomly 
assigned to study intervention  according to the treatment to which the participant s are assig ned 
and w ere exposed to at least one dose . The primary and key secondary efficacy analysis will be 
guided by 2 estimands, the “ treatment regimen ” estimand  and the “efficacy” estimand to support 
global regulatory submissions and publications . For the “treatment regimen ” estimand, the 
analysis will be conducted using FAS . To minimize missing data, participants  randomly assigned 
to study intervention  who prematurely discontinue study treatment will be encouraged to remain 
in the study , however, some parti cipants may choose to permanently discontinue from the study 
which will lead to missing endpoints. Details on handling missing values can be found in 
Missing Value Imputation section. For the “efficacy ” estimand , the analysis  will be conducted 
using the EA S. 
Safety analysis will be conducted using the SS. Selected safety analyses may be conducted after 
excluding the data after permanent discontinuation of the study intervention . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 63 Unless otherwise noted, all tests of treatment effects wil l be conducted at a 2 -sided alpha level of 
0.05, and the confidence interval will be calculated at 95%, 2 -sided. In statistical summaries and 
analyses, participant s will be analyzed as randomized. Countries in similar geographic regions 
with fewer than 10 participant s, based on the all -randomized population, will be pooled to 
achieve a pooled country of at least 10 participant s. All analyses using country in the model will 
use a pooled country, unless otherwise specified. The final pooling by country and ge ographic 
region will be finalized prior to data lock . 
Baseline  is defined as the last non  missing measurement at or before the randomization visit 
(Visit 2) unless otherwise specified.  
Analysis of covariance  will be used to analyze continuous variables col lected only at baseline 
and endpoint. The model will include treatment and strata (pooled country/geographic region, 
AHI stratum [moderate (AHI ≥15 and AHI <30), severe (AHI ≥ 30)] and gender) as fixed effects 
and baseline as a covariate. The ANCOVA model for AHI analysis will include baseline AHI 
instead of the AHI stratum as a fixed covariate.  
The MMRM analysis , a restricted -maximum -likelihood -based  model , will be used to analyze 
continuous longitudinal variables. All the longitudinal observations  at each  scheduled 
postbaseline visit will be included in the analysis . The model will include the fixed class effects 
of treatment, strata (pooled country/geographic region and gender), visit, and treatment -by-visit 
interaction, as well as the continuous, fixed c ovariate of baseline value. For analyses of variables 
other than AHI, the AHI stratum will also be included in the model. Significance tests will be 
based on least -squares means and Type III tests . 
For continuous measures, summary statistics may include sample size, mean, standard deviation , 
median, minimum, and maximum for both the actual and the change from baseline 
measurements. Least -square means and standard errors derived from the analysis models will 
also be displayed for the change from ba seline measureme nts. Treatment comparisons will be 
displayed showing the treatment difference least-square  means and the 95% confidence interval s 
for the treatment differences, along with the p -values for the treatment comparisons.  
For categorical measures , summary statistics may include sample size, frequency, and 
percentages. Fisher’s exact test or Pearson’s chi -square test will be used for treatment 
comparisons  unless otherwise specified . 
Missing values for the primary and multiplicity adjusted endpoints  at Week 52 and at Week 48 
for SBP will be handled as follows. For efficacy analysis relative to the “efficacy” estimand, no 
explicit imputation will be performed.  For efficacy analysis relative to the “treatment regimen ” 
estimand, missing values will be i mputed using multiple imputation based on the reason of 
intercurrent events. The statistical inference over multiple imputations will be guided by the 
method proposed by Rubin (1987) . The intercurrent events and the resulting missing values will 
be handled  as follows:  
Intercurrent events  Strategy to handle 
intercurrent events  Assumptions for 
missing values  Methods to handle 
missing values  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 64 Study  DC due to the 
COVID -19 pandemic 
(after other reasons 
for missing data are 
ruled out)  or incorrect  
study procedure  
leading to  invalid 
measurements 
ascertained while on 
treatment   Hypothetical  MAR  Use observed data 
without any 
imputation  
All other study  
discontinuations  Treatment policy  MNAR  Multiple imputation. 
Details will be 
indicated in SAP  
Abbreviations: COVID -19 = coronavirus disease -2019 ; DC  = discontinuation; MAR  = missing at random; 
MNAR  = missing not at random.  
Handling of missing, unused, and spurious data are addressed prospectively in the overall 
statistical methods described in the protocol and in  the SAP, where appropriate. Adjustments to 
the planned analyses are described in the final CSR.  
9.3.2.  Primary Analysis   
The primary objective of this study is to test the hypothesis that tirzepatide at the MTD  (10 mg or 
15 mg) is superior to placebo for participant s with moderate to severe OSA on the mean  AHI 
reduction from baseline to Week 52.  
The primary analysis guided  by the “treatment regimen ” estimand will use FAS. Missing values 
will be imputed based on the strategy to handle intercurrent events  described in Section 9.3.1 , 
and more details about the imputation methods will be provided in the SAP . After the 
imputation, the primary efficacy comparison will be based on the contrast between tirzepatide at 
the MTD ( 10 mg or 15  mg) and placebo from the ANCOVA analysis of mean  change from 
baseline to Week 52 in AHI using FAS as described in Section  9.3.1 . 
The primary analysis guided by the “efficacy” estimand will use EAS. The efficacy comparison 
will be based on the contrast between tirzepatide at the MTD (10  mg or 15  mg) and placebo at 
Week 52 (Visit 11) from the MMRM analysis of mean  change from baseline in AHI using EAS  
as described in Section 9.3.1. More details about the model will be provided in the SAP.  
Analysis aligned to each estimand will be evaluated at the full significance level of 0.05.  
9.3.3.  Analysis of Key Secondary Endpoints   
The a nalyses for key secondary endpoints as in Section 3 will be perfor med for both the 
“treatment regimen ” and “efficacy ” estimand as described in Section 9.3.1  using the graphical 
testing scheme. The details of graphical testing scheme will be described in the SAP.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 65 The analysis  of the hierarchical combination PRO endpoint will be performed with the 
Finkelstein -Schoenfeld method, and the win ratio (Pocock et al. 2012) will be reported as the 
measure of treatment effect.  
The last measurement prior to randomization for all three PRO endpoints will be used as 
baseline. For the “treatment regimen ” estiman d, missing values at Week 52 will be imputed 
through multiple  imputations based on the reason of missingness as described in Section 9.3.1 . 
Analysis of percent  change in AHI , percent change from baseline in body weight, CRP at the 52 -
week visit and change in SBP at the 48 -week visit will be conducted in a manner similar to the 
primary efficacy analyses with baseline AHI stratum  added in the mo del, and baseline of the 
corresponding variable as a covariate.  Analysis of  percent  change in AHI  will not include the 
baseline AHI stratum . 
Comparisons at the 52 -week visit between the treatments relative to the proportion of 
participant s achieving ≥ 50% AHI reduction and AHI< 5 or (AHI ≥ 5 and AHI ≤ 14 and ESS ≤ 
10) will be conducted using logistic regression analysis including  terms  for treatment, pooled 
country, gender, and  baseline AHI as a covariate.  
Analysis aligned to each estimand will be evaluated at the full significance level of 0.05 
contingent on reaching statistical significance of the primary objective . 
9.3.4.  Treatment Group Compara bility   
9.3.4.1.   Participant Disposition   
Participants  who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported for each ISA. A detailed description of participant 
disposition and the reasons for discontinuation will be summarized by treatment group for each 
ISA at the end of the study. Intervention -specific analyses will be detailed in each respective 
ISA. 
9.3.4.2.  Participant Characteristics   
Participant characteristics and baseline clinical measures will be summarized for each treatment . 
For all participant characteristics, the summaries will include  descriptive statistics for continuous 
measures ( for example, sample size, mean, standard deviation , median, minimum, and 
maximum) and for categorical measures ( for example, sample size, counts and percentages). 
Additional intervention -specific analyses wi ll be specified in each respective ISA.  
9.3.4.3.  Concomitant Therapy   
Concomitant  medications used during the study will be summarized for each ISA.  
9.3.5.  Safety Analyse s  
Unless specified otherwise, safety assessments will compare  safety of tirzepatide at the MTD  (10 
mg or 15 mg)  with placebo irrespective of adherence to study intervention . Thus, safety analyses 
will be  conducted using the SS.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 66 9.3.5.1.  Adverse Events   
Adverse events will be classified by system organ class and preferred term as defined by the 
Medical  Dictionary for Regulatory Activities.  
All conditions  existing prior to randomization at Visit 2 will be used as baseline. The 
postbaseline visits during the placebo -controlled phase will be included as the postbaseline 
period for analysis.  
For events  that are gender specific, the denominator and computation of the percentage will only 
include participants of the given gender.  
9.3.5.2.  Hypoglycemic Events   
Incidence of documented symptomatic hypoglycemia events and severe hypog lycemia will be 
summarized  and compared between tirzepatide at the MTD (10 mg or 15  mg) and placebo. Rate 
of hypoglycemic episodes will also be analyzed . Some analyses may be conducted excluding 
data after introducing another antihyperglycemic therapy . 
9.3.5.3.  Gastrointestinal Events   
Summaries and analyses for incidence and severity of nausea, vomiting, and diarrhea will be 
provided by each treatment . 
9.3.5.4.  Adjudicated Cardiovascular Events   
Listings  of deaths, myocardial infarctions, strokes, and hospitalizat ions for unstable angina or 
heart failure confirmed by an independent Clinical Endpoint Committee ( CEC ) will b e provided.  
9.3.5.5.  Central Laboratory Measures and Vital Signs   
Values and change from baseline to postbaseline values of central laboratory measures and vital 
signs will be summarized and compared between tirzepatide  at the MTD (10  mg or 15  mg) and 
placebo at each scheduled visit.  
9.3.5.6.  Analysis of C-SSRS  Data   
Suicide -related thoughts and behaviors occurring during t reatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide ( The 
Columbia Lighthouse Project, 2013 ). 
9.3.6.  Evaluation of Immunogenicity   
The frequency  and percentage of participants with preexisting ADA and with TE ADA+ to 
tirzepatide will be tabulated. Treatment -emergent ADAs are defined as those with a titer 2 -fold 
(1 dilution) greater than the minimum required dilution (1:10) of the ADA assay if no A DAs 
were detected at baseline (treatment -induced ADA) , or those with a 4 -fold (2 dilutions) increase 
in titer compared with baseline if ADAs were detected at baseline (treatment -boosted ADA). For 
the TE ADA+ participants, the distribution of maximum titers  will be described. The frequency 
of neutralizing antibodies may also be tabulated in TE ADA+ participants.  The relationship 
between the presence of antibodies and the PK parameters and PD response including safety and 
efficacy to  tirzepatide  may be assess ed. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 67 9.3.7.  Other Analyses   
9.3.7.1.  Health Economics   
Analyses of actual and change from baseline in PRO scores will b e conducted using linear 
models with baseline PRO scores, treatment, stratification factors and other factors that may be 
considered relevant. These variables will be specified in the SAP.  
9.3.7.2.  Subgroup Analyses   
The following subgroups will be analyzed using the “efficacy ” estimand on percent  change in 
AHI values  from baseline to 52 week visit  if there are sufficient numbers of participant s in each 
treatment by subgroup (for example, 10%):  
 Age (50 years, 50 years),  
 Baseline OSA severity (Moderate, Severe) , 
 Race , 
 Ethnicity , 
 Country,  
 Gender (Male or Female) , 
 Baseline BMI (<30, ≥30 and <35, ≥35 and <40, ≥40 kg/m2), and  
 Baseline ESS (ESS ≤10, ESS>10). 
Analyses  for percent change from baseline in AHI will be performed using an MMRM model 
that includes the same fixed effects given for the primary analysis model plus factors of 
subgroup, 2 -way interaction of subgroup and treatment, 2 -way interaction of subgroup an d visit, 
and 3 -way interaction of treatment, visit and subgroup. The interaction of subgroup and 
treatment at the primary endpoint (Week 52) will be evaluated to assess the treatment by 
subgroup interaction. When analyzing OSA severity (Moderate, Severe) a s a subgroup, the 
baseline AHI will be not be included as a covariate to avoid confounding.  Additional subgroup 
analyses may also be performed . 
More d etails on other analyses will be described in the SAP.  
9.4. Interim Analys is  
Based on the projected enrollment, approximately 3 interim analyses of safety will be conducted. 
The first interim analysis is planned to occur when approximately 20% of the ant icipated number 
of participants are random ly assigned to study intervention  or 6 months after the first participant 
is random ly assigned to study intervention , whichever occurs later , from one of the ISAs.  
Subsequent reviews will follow approximately every  6 months throughout the study.  
Only t he DMC is authorized to evaluate unblinded interim analyses. Study sites will receive 
information about interim results only if they need to know for the safety of their participants.  
Unblinding details are specified i n SAP and/or a separate unblinding plan document.  
The DMC charter will describe the specific parameters of the planned interim analysis . 
See Section 10.1.5 , Appendix 1  And the DMC Charter for details related to the DMC.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 68 The timing of dissemination of data summaries based on interim analyses is addressed in  Section 
10.1.6 , Appendix 1 . 
9.5. Sample Size Determination   
Approximately  206 participants per ISA will be randomly assigned to either tirzepatide or 
placebo in a 1:1 ratio (approximately 10 3 participants per treatment arm), and the statistical 
power is evaluated for the primary efficacy endpoint and key secondary combination PRO 
endpoint at a 2 -sided significance level of 0.05. This samp le size will provide  
 At least 90% power  to demonstrate superiority of tirzepatide at the MTD (10 mg or 15  
mg) to placebo for the mean  percent change from baseline in AHI, assuming 50% 
improvement, with a common standard deviation of 50 %, and a dropout rate  of 25%  
 at least 90% power  to demonstrate superiority of tirzepatide at the MTD  (10 mg or 15  
mg) to placebo for the hierarchical combination PRO endpoint using Finkelstein -
Schoenfeld method (Finkelstein and Schoenfeld 199 9) with a dropout rate of 25%  
An up per limit of approximately  70% enrollment of male participants  will be used to ensure a 
sufficiently large sample of female participants.  
The sample size and power for the key secondary hierarchical combination PRO endpoint is 
estimated through simulations under the following assumptions  (Blackman  et al. 2016,  Weaver  
et al. 2021) : 
Variable  Placebo  Tirzepatide at 
the MTD  
(10 mg or 
15 mg) Definition of Win  
FOSQ -10 – 
change from 
baseline (mean  
± SD) 1.24 ± 1.84 1.95 ± 1.84 If the change from baseline FOSQ -10 
for TZP at MTD (10  mg or 15  mg) 
minus  chang e from baseline FOSQ -10 
for placebo ≥2.2  
FOSQ 
Vigilance – 
change from 
baseline (mean  
± SD) 0.3 ± 0.5 0.5 ± 0.5 If the change from baseline FOSQ 
Vigilance for TZP at MTD (10  mg or 
15 mg) minus change from baseline 
FOSQ Vigilance for placebo ≥0.44  
FOSQ Activity 
Level – change 
from baseline 
(mean  ± SD) 0.3 ± 0.5 0.5 ± 0.5 If the change from baseline FOSQ 
Activity Level for TZP at MTD (10  mg 
or 15  mg) minus change from baseline 
FOSQ Acti vity Level for placebo ≥0.44  
Abbreviations: FOSQ  = Functional Outcomes of Sleep Questionnaire ; FOSQ -10 = FOSQ 10 -item short form ; 
MTD  = maxim um tolerated dose; SD = standard deviation; TZP = tirzepatide . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 69 10. Supporting Documentation and Operational Considerat ions  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
This study will be conducted in accordance with the protocol and with the following:  
 Consensus ethical principles derived from international guidelines including t he 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
International Ethical Guidelines  
 Applicable ICH GCP Guidelines  
 International Organization for Standardization (ISO) 14155  
 Applicable laws and regulations  
The protocol, protocol amendments, ICF s, IB, and other relevant documents ( for example , 
advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved 
by the IRB/IEC  before the study is initiated.  
Any amendments to the protocol w ill require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard  to study participants.  
Protocols and any substantial amendments to the protocol will require health author ity approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study 
participants . 
The investigator  will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC  
 Notifying the IRB/IEC of SAEs  or other significant safety findings as required by 
IRB/IEC procedures  
 Providing oversight of study conduct for participa nts under their responsibility and 
adherence to requirements of 21 C ode of Federal Regulations , ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations  
Investigator sites a re compensated for participation in the study  as detailed in the clinical trial 
agreement . 
10.1.2.  Financial Disclosure   
Investigators  and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. In vestigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 70 10.1.3.  Informed Consent Process   
The investigator or the investigator’s  representative will explain the nature of the study , 
including the risks and benefits,  to the participant or the participant’s  legally authorized 
representative  and answer all  questions regarding the study.  
Participa nts must be informed that their participation is voluntary. Participants or their legally 
authorized representative s will be required to sign a statement of informed consent that meets the  
requirements of 21 Code of Federal Regulations  50, local regulation s, ICH guidelines, privacy 
and data protection requirements, where applicable, and the I RB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant  was enter ed in the study and the d ate the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants  must be reconsented to the most current version of the ICF(s) during th eir 
participation in the study.  
A copy of the ICF(s) must  be provided to the participant or the participant’s legally authorized 
representati ve and is kept on file . 
Participants who are rescreened are required to sign a new ICF.  
10.1.4.  Data Protection   
Participants will be assigned a unique identifier by the sponsor. Any participant records , datasets  
or tissue samples  that are transferred to the sponsor will contain the identi fier only; participant 
names or any information which would make the participant identi fiable will not be transferred.  
The participant must be informed that the participant’s  personal study -related data will be used 
by the sponsor in accordance with local data protection law. The level of disclosure must also b e 
explained to the participant  who will be required to give consent for their data to be used as 
described in the informed consent . 
The participant must be informed that their medical records may be e xamined by Clinical 
Quality  Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
The sponsor has processes in place to ensure data protection, information security and data 
integrity . These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data security breach.  
10.1.5.  Committees Structure   
Prospective adjudication of major adverse CV events and pancreatic AEs will be performed by 
the independent adjudication committees for this study . 
Section s 10.1.5.1  and 10.1.5.2 , Appendix 1 outline additional information on pancreatic and CV 
adjudication . 
An independent DMC for the interim analysis (Section 9.4) will include members with no 
conflict of financial interest.  An independent D MC with members all external to the sponsor will 
be used to monitor participant safety in an unblinded fashion. For details on the DMC, refer to 
the DMC charter.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 71 10.1.5.1.  Cardiovascular Adjudicated Events   
Deaths  and nonfatal CV A Es will be adjudicated by a committee blinded to treatment 
assignment. The nonfatal CV A Es to be adjudicated include:  
 myocardial infarction  
 hospitalization for unstable angina  
 hospitalization for heart failure  
 coronary interventions (such as coronary artery bypass graft or percutaneous coronary  
intervention), and  
 cerebrovascular events, including cerebrovascular accident (stroke) and transient  
ischemic attack.  
10.1.5.2.  Pancreatitis Adjudicated Event   
Acute pancreatitis is defined as an AE of special interest  in this trial  (Section 8.3.3 ). 
The diagnosis  of acute pancreatitis requires 2 of the following 3 features:  
 abdominal pain, characteristic of acute pancreatitis (generally located in the epigastrium 
and radiates to the back in approximately half the cases) (Banks and Freeman 2006; 
Koizumi et al. 2006); the pain is often associated with nausea and vomiting  
 serum amylase (total and/or pancreatic) and/or lipase ≥3X ULN, and  
 characteristic findings of acute pancreatitis on CT scan or MRI.  
All suspected  cases of acute or chronic pancreatitis wil l be adjudicated by a committee  blinded to 
treatment assignment . In addition, A Es of severe or serious abdominal pain of unknown etiology 
will also be submitted to the adjudication committee to assess for possible pancreatitis or other 
pancreatic disease. Relevant data from participants with acute or chronic pancreatitis and those 
with severe or serious abdominal pain will be entered into a specifically designed CRF page. The 
adjudication committee representative will enter the results of adjudication in a corresponding 
CRF page.  
10.1.6.  Dissemination of Clinical Study Data   
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly availa ble websites where required by local law or regulation.  
The summary of results will be posted within the time frame specified by local law or regulation. 
If the study remains ongoing in some countries and a statistical analysis of an incomplete data set 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not yet unblinded), the summary of results 
will be submitted within 1 year after the end of the study global ly or as soon as available, 
whichever is earlier.  
The publication policy for Study GPIF is outlined in  Section 10.1.10 , Appendix 1 and further 
described in the Clinical Trial Agreement.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 72 Data  
The sponsor provides access to all individual participant data collected during the trial, after 
anonymization, with the exception of PK or genetic data.  
Data are available to request 6 months after the indication studied has been approved in the US 
and EU and after primary publication acceptance, whichever is later. No expiration date of data 
requests is currently set once data are made available.  
Access is provided after a proposal has been approved by an independent review committee 
identified for this purpose and after receipt of a signed data sharing agreement.  
Data and documents, including the study protocol, SAP, CSR , and blank or annotated CRFs , will 
be provided in a secure data sharing environment  for up to 2 years per proposal.  
For details on submitting a request, see the instructions provided at www.vivli.org.  
10.1.7.  Data Quality Assurance   
All participant data relating to the study will be recorded on printed or electronic CRF s unless 
transmitted  to the sponsor or designee electronically ( for example , laboratory data). The 
investigator  is responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
The investigator  must maintain accurate documentation (source data) that supports the 
information entered in  the CRF.  
The investigator  must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Quality tolerance limits (QTLs) will be pre -defined to identify systematic issues that can impact 
participa nt safety and/or reliability of study results. These pre -defined parameters will be 
monitored during the study and important excursions  from the QTLs and remedial actions taken 
will be summarized in the CSR . 
Monitoring details describing strategy ( for exam ple, risk -based initiatives in operations and 
quality such as risk management and mitigation strategies and analytical risk -based monitori ng), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques are provided in the Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study includin g quality 
checking  of the data.  
The sponsor assumes accountability for actions delegated to other individuals ( for example , 
contract r esearch organizations ). 
Study  monitors will perform ongoing source data verification to confirm that data transcribed  
into the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regu latory requirements.  
Records and documents, including signed ICFs, pe rtaining to the conduct of this study must be 
retained  by the investigator for the time period outlined in the Clinical Trial Agreement unless 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 73 local regulations or institutional policies require a longer retention period. No records may be 
destroyed during  the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party without written notification to the sponsor . 
In addition, sponsor  or its representatives will periodically check a sample of the participant  data 
recorded  against source documents at the study site. The study may be audited by sponsor  or its 
representatives, and/or regulatory agencies at any time. Investigators will be given notice before 
an audit occurs.  
Data Capture System  
The inve stigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An EDC  system will be used in this study for the collection of CRF data. The investigator 
maintains a separate source for the d ata entered by the investigator or designee into the 
sponsor -provided EDC system. The investigator is responsible for the identification of any data 
to be considered source and for the confirmation that data reported are accurate and complete by 
signing th e CRF . 
Additionally, COA data ( clinician -reported  outcome instrument ) for suicidality assessments  will 
be collected by the authorized study personnel , via a paper source document and will be 
transcribed by the authorized study personnel  into the EDC system . 
Additionally, electronic COA data ( participant -focused outcome instrument ) will be directly 
recorded by the participant , into an instrument ( for example, handheld  smart phone or tablet ). 
The electronic  COA data will serve as the source documentation  and the investigator does not 
maintain a separate, written or electronic record of these data.  
Data collected via the sponsor -provided data capture system(s) will be stored at third parties.  The 
investigator will have continuous access to the data during the s tudy and until decommissioning 
of the data capture system (s). Prior to decommissioning, the investigator will receive or access 
an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored  electronically in 
the central vendor’s database system and reports/electronic transfers  will be provided to the 
investigator for review and retention. Data will subsequently be transferred from the central 
vendor  to the sponsor  data warehouse.  
Data collected on the actigraphy device will be transferred electronically to the sponsor data 
warehouse, via a third party.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global PC 
management system.  
10.1.8.  Source Documents   
Source documents provide evidence for the existence of the participant and substantiate the 
integrity  of the data collected. Source documents are filed at the investigator’s site . 
Data reported  on or entered in the CRF and are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 74 may need to request previous medical records or transfer records, depen ding on the study. Also, 
current medical records must be available.  
Definition  of what constitutes source data can be found in  Section 10.1.7 , Appendix 1 . 
10.1.9.  Study and Site Start and Closure   
First Act of Rec ruitment  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  The first act of recruitment is the first site open  and will  be the study start date.  
Study or Site Termination  
The sponsor or sponsor’s  designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents  and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:  
 For study termination:  
o Discontinuation of further study intervention development  
 For site termination:  
o Failure of the investigator to comply wi th the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor ’s procedures, or GCP guidelines  
o Inadequate recruitment (evaluated after a reasonable amount of time)  of 
participants by the investigator  
o Total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason f or termination or suspension, as specified by the applicable 
regulatory requirements. The investigator shall promptly inform the participant  and should assure 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy   
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.11.  Investigator Information   
Researchers  with appropriate education, training, and experience, as determined by the sponsor, 
will participate as investigators in this clinical trial . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 75 10.1.12.  Sample Retention   
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of tirzepatide or after tirzepatide becomes commercially available.  
Sample Type   Custodian   Retention Period After Last Participant  
Visita  
Exploratory Biomarker 
Samples  Sponsor or 
Designee   15 years   
PK Samples  Sponsor or 
Designee   2 years   
Genetics  Sponsor or 
Designee   15 years   
Immunogenicity  (ADA) 
Samples  Sponsor or 
Designee   15 years   
Abbreviations:  ADA = antidrug antibody ; PK = pharmacokinetic . 
aRetention periods may differ locally.  
 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 76 10.2. Appendix 2: Clinical Laboratory Tests   
The tests detailed in the table below will be performed by the central laboratory . 
Local laboratory results are only required in the event that the central laboratory results ar e not 
available in time for either study intervention administration and/or response evaluation. If a 
local sample is required, it is important that the sample for central analysis is obtained at the 
same time.  
In circumstances where the sponsor approves l ocal laboratory testing in lieu of central laboratory 
testing (in the table below), the local laboratory must be qualified in accordance with applicable 
local regulations.  
Protocol -specific requirements for inclusion or exclusion of participants are detail ed in Section 5 
of the protocol.  
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations.  
Investigators must document their  review of the laboratory safety results . 
Laboratory results  that could unblind the study will not be reported to investigative sites or other 
blinded personnel . 
Clinical Laboratory Tests   Comments  
Hematology  Assayed by Lilly -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Leukocytes (WBCs)    
Differential    
Percent and/or Absolutes Count of:    
  Neutrophils, segmented    
  Bands    
  Lymphocytes    
  Monocytes    
  Eosinophils    
  Basophils    
Platelets    
Cell morphology (RBCs and WBCs)    
Clinical Chemistry  Assayed by Lilly -designated laboratory  
Sodium    
Potassium    
Chloride    
Bicarbonate    
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 77 Clinical Laboratory Tests   Comments  
Total bilirubin    
Direct bilirubin    
ALP    
ALT    
AST    
BUN    
Creatinine    
CK   
Uric acid    
Albumin    
Calcium    
Glucose    
Lipid Panel  Assayed by Lilly designated laboratory.  
Cholesterol    
Triglycerides    
HDL -C .  
LDL -C Generated by Lilly -designated laboratory.  
If Triglycerides are >400; direct  LDL will be 
measured.  
VLDL -C Generated by Lilly -designated laboratory.  
Hormones (female)    
Serum Pregnancy  Assayed by Lilly -designated laboratory.  
Urine Pregnancy  Assayed and Evaluated locally  
FSH  Assayed by Lilly -designated laboratory.  
Urine Chemistry   Assayed by Lilly -designated laboratory.  
Albumin    
Creatinine    
Calculations  Generated by Lilly -designated laboratory.  
eGFR (CKD -EPI)    
UACR    
PK Samples – Tirzepatide  Assayed by Lilly -designated laboratory.  
Results will not be provided to the investigative sites.  
Immunogenicity (ADA) Samples  Assayed by Lilly -designated laboratory.  
Results will not be provided to the investigative sites.  
  Anti-tirzepatide  antibodies OR Tirzepatide  antibodies   
  Anti-tirzepatide  antibodies neutralization OR Tirzepatide 
antibodies  neutralization   
Additional Testing  Assayed by Lilly -designated laboratory.  
HbA1c   
Calcitonin   
Pancreatic Amylase   
Lipase   
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 78 Clinical Laboratory Tests   Comments  
Insulin  Results will not be provided to the investigative sites.  
C-Peptide  Results will not be provided to the investigative sites.  
Free Fatty Acids  Results will not be provided to the investigative sites.  
hsCRP  Results will not be provided to the investigative sites.  
Cystatin -C  
TSH   
Stored Samples  Assayed by Lilly -designated laboratory.  
Results will not be provided to the investigative sites.  
Genetics Sample   
Exploratory Biomarker Samples   
  Serum    
  Plasma (EDTA)    
  Plasma (P800)     
Abbreviations:  ADA = antidrug antibody;  ALP = alkaline phosphatase ; ALT = alanine aminotransferase;; AST =  
aspartate aminotransferase;  BUN = blood urea nitrogen;  CK = creatinine kinase , CKD -EPI = Chronic Kidney 
Disease -Epidemiolog y; EDTA  = ethylenediaminetetraacetic acid; eGFR  = estimated glomerular filtration  rate; 
FSH = follicle -stimulating hormone ; HbA1c  = hemoglobin A1c ; HDL -C = high-density lipoprotein  cholesterol ; 
hsCRP = C -Reactive Protein, high -sensitivity ; IWRS = interactive web -response system;  LDL-C = low-density 
lipoprotein cholesterol ; PK = pharmacokinetics ; RBC  = red blood cells ; TSH = thyroid -stimulating hormone ; 
UACR = urine albumin/creatinine ratio; VLDL -C = very-low-density lipoprotein  cholesterol ; WBC  = white 
blood cells . 
10.2.1.  Laboratory Samples to be Obt ained at the Time of a Systemic Hypersensitivity 
Event   
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected  for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hypersensitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain  follow -up pre -dose samples at the next regularly scheduled labo ratory sample collection 
(ideally prior to the next dose after the event) to assess post -event return -to-baseline values.  
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 79 Timing  Sample Type  Laboratory Test a 
Collect from 30 minutes to 4 hours 
after the start of the event.  
● Note: The optimal 
collection  time is from 1 to 2 
hours after the start of event.  Serum  total tryptase  
Serum  complements ( C3, C3a, and C5a)  
Serum  cytokine panel ( IL-6, IL‐1β, IL‐10 or any cytokine panel 
that includes these 3 cytokines)  
Collect only if not already collected 
on the same day as the event.  
● Note: If collecting, collect 
up to 12 hours after the start of 
the event.  Serum  Tirzepatide ADA  
Serum/plasma  Tirzepatide concentration  
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.  
a All samples for hypersensitivity testing will be assayed by Lilly -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation.  
What  information to record  
Record  the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests locally, if clinically indicated, for acute study 
participant management.  
 
 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 80 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
 The definitions and procedures detailed i n this appendix are in accordance with 
International Organization for Standardization (ISO) 14155.  
 Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
 The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.1  for the list of 
sponsor medical devices).  
10.3.1.  Definition of AE   
AE Definition  
 An AE is any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product . 
 An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory finding) i n study participants, users, or 
other persons, whether or not related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator 
and events related to the procedures involved except fo r events in users or other 
persons, which only include events related to investigational devices.   
 
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for ex ample , ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not related 
to progression of underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New condition detected or diagnosed after study intervention administration even 
though it may have been present b efore the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of study intervention , including signs, symptoms, or 
clinical sequalae.  
 Lack of efficacy or failure of expected  pharmacological action per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 81 However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they f ulfill the definition o f an AE or SAE.   
 
Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
 Medical  or surgical procedure ( for example , endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.   
10.3.2.  Definition of SAE   
An SAE is defined as any untoward m edical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing  hospitalization  
 In general, hospitalization signifies that the participant has been admitted to  hospital or 
emergency ward (usually involving at least an overnight stay) for observation and/or 
treatment that would not have been appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospitalization are A Es. If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious. When 
in doubt as to whether hospitalization occurred  or was necessary, the AE should be 
considered serious.  
 Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a s ubstantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 82 and acciden tal trauma ( for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal  death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations such as important medical 
events that may not be immediately life -threatening or result in death or hospitalization 
but may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definiti on. These events should 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi talization, or development of drug dependency or 
drug abuse.   
g. Resulted in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.   
 
10.3.3.  Definition of Product Complaints   
Product Complaint  
 A PC is any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness or performance of a 
study  intervention . When the ability to use the study intervention safely is impacted, 
the following are also PCs: 
o Deficiencies in labeling information, and  
o Use errors for device or drug-device combination products due to ergonomic 
design elements of the product.  
 Product com plaints related to study inte rventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor quality, and to facilitate process and 
product improvements.  
 Investigators will instruct p articipants to contact the site as soon as possible if he or she 
has a PC or problem with the study inte rvention  so that the situation can be assessed.  
 An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 83 10.3.4.  Recordi ng and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and PC Recording  
 When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospital progress notes, laboratory reports, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant AE/ SAE /PC information in the 
participant’s medical records, in accordance with the invest igator’s normal clinical 
practice . AE/SAE information is reported o n the appropriate  CRF  page and PC 
information is reported on the PC Form . 
Note: An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to sponsor or designee  in lieu of completion of the CRF page  for AE/SAE and 
the PC Form for product complaints . 
 There may be instances when copies of medical records for certain cases are requested 
by sponsor or designee . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records bef ore 
submission to sponsor or designee . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE .  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:  
 Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living . 
 Moderate:  A type of AE that is usually alleviated with additional specific therapeu tic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant . 
 Severe: A type of AE that interrupts usual activities of daily living, or signi ficantly 
affects clinical status, or may require intensive therapeutic intervention . An AE that is 
assessed as severe should not be confused with a n SAE. Severe is a category utilized 
for rating the intensity of an event; and both A Es and SAEs can be asses sed as severe.  
An event is defined as “serious ” when it meets at least one of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.   
 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 84 Assessment of Causality  
 The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  The investigator will use clinical judgment to 
determine the relationship . 
 A “reasonable possibility ” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administr ation will be considered and investigated.  
 The investigator will also consult the IB in their assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to sponsor or designee . However, it 
is very important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to sponsor or designee . 
 The investigator may change their opinion of causality in light of follow -up 
information and send a n SAE follow -up report with the updated causality assessment.  
 The causality ass essment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -Up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by sponsor or 
designee  to elucidate the nature and/or causality of the AE or SAE as fully as possible . 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period,  the inv estigator will provide sponsor or designee  with a copy of any 
post-mortem findi ngs including histopathology.  
10.3.5.  Reporting of SAEs   
SAE Reporting via an Electronic Data Collection To ol 
 The primary mechanism for reporting an SAE will be the electronic data collection 
tool. 
 If the electronic system is unavailable, then the site will use the SAE paper form (see 
next section) in order to report the event within 24 hours.  
 The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 85  After the study is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a n SAE paper form (see next 
sectio n) or to the sponsor or desi gnee  by telephone.  
 Contacts for SAE reporting can be found on the SAE form.  
 
SAE Reporting via Paper Form  
 Facsimile transmission of the SAE paper form  is the preferred method to transmit this 
information to the sponsor or designee . 
 Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE reporting can be found on the SAE form .  
10.3.6.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
 Prompt notification by the investigator to the sponsor of a n SAE is essential so 
that legal obligations and ethical responsibilities toward the safety of 
participants and the safety of a study intervention under clinical investigation 
are met.  
● The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC , and investigators.  
● An investigator who receives an investigator safety report describing a n SAE or 
other specific safety information ( for example , summary or listing of SAEs) 
from the spo nsor will review and then file it along with the IB and will notify 
the IRB/IEC, if appropriate according to local requirements.   
10.3.7.  Special Safety Topics   
10.3.7.1.  Hypoglycemia   
Participants will be trained by authorized study personnel about signs and symptoms of 
hypoglycemia and how to treat hypoglycemia , and how to collect appropriate information for 
each episode  of hypoglycemia . 
Hypoglycemia may be identified by spontaneous reporting of symptoms from participants 
(whether confirmed or unconfirmed by simultaneous glucose values) or by blood glucose 
samples  collected during study visits.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 86 All participants who develo p diabetes during the study will be provided with glucometers. 
Participants without diabetes may, at the investigator’s discretion, be given glucometers to assist 
in the evaluation of reported symptoms consistent with hypoglycemia. Participants receiving 
glucometers will be provided a diary to record relevant information (for example, glucose values, 
symptoms).  
Hypoglycemic episodes will be recorded in the eDiary  and should not be recorded as AEs unless 
the event meets serious criteria. If a hypoglycemic event meets severe criteria (see definition 
below), it should be recorded as serious on the AE and SAE CRFs, and reported to Lilly as an 
SAE.  
Investigators should use the following classification of hypoglycemia  (ADA 2020) : 
 
Level 1 hypoglycemia:  
Glucose <70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L):  Level 1 hypoglycemia 
can alert a person to take action such as treatment with fast -acting carbohydrates. Providers 
should continue to counsel participants to treat hypoglycemia at this glucose alert value . 
Level 2 hypoglycemia:  
Glucose <54 mg/dL (3.0 mmol/L):  Level 2 hypoglycemia is  also referred to as documented 
or blood glucose confirmed hypoglycemia  with glucose <54 mg/dL (3.0 mmol/L). This 
glucose threshold is clinically relevant regardless of the pres ence or absence of symptoms of 
hypoglycemia.  
Level 3 hypoglycemia:  
Severe hypoglycemia (in adults): A severe event characterized by altered mental and/or 
physical status requiring assistance for treatment of hypoglycemia. For example,  
participants  had altered  mental  status,  and could not assist in their own care, or were  
semiconscious or unconscious, or experienced  coma  with or without  seizures,  and the 
assistance of another person was needed to actively administer carbohydrate, glucagon, or 
other resus citative  actions.  Glucose  measurements  may not be available during  such an event, 
but neurological recovery  attributable to the restoration of  glucose concentration  to normal  is 
considered  sufficient  evidence  that the event was induced by  a low glucose concentration.  
 The determination of a hypoglycemic event as an episode of severe hypoglycemia, as 
defined above, is made by the investigator based on the medical need of the 
participant to have required assistance and is not predicated on the report of a 
participant simply having received assistance.  
 If a hypoglycemic event meets the criteria of severe hypoglycemia, the investigator 
must record the event as serious on the AE CRF and report it to Lilly as an SAE.  
Nocturnal hypoglycemia :  
Nocturnal hypoglycem ia is a hypoglycemia event (including severe hypoglycemia) that 
occurs at night  and presumably during sleep.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 87 To avoid duplicate reporting, all consecutive BG values <70 mg/ dL (<3.9 mmol/L)  occurring 
within a 1 -hour period may be considered to be a single hypoglycemic event 
(Weinberg  et al. 2010; Danne et al. 2013).  
10.3.7.2.  Hypersensitivity Reactions   
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are r eceiving study intervention. It is recommended that 
participants who experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as described in Section  10.2.1 . Laboratory results are provided to the sponsor via the 
central laboratory . 
10.3.7.3.  Injection -Site Reactio ns  
Symptoms and signs of a local ISR may include erythema, induration, pain, pruritus, and edema.  
If an ISR is reported by a participant or parent or guardian or site staff, the ISR CRF will be used 
to capture additional information about this reaction, for example, injection site pain, degree and 
area of erythema, induration, pruritis and edema.  
At the time of AE occurrence, samples will be collected for measurement of tirzepatid e ADAs 
and tirzepatide concentration . 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 88 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
Word/Phrase  Definition  
Women of child 
bearing potential  Females are considered a WOCBP if  
 they have had at least 1 cycle of menses, or  
 they have Tanner 4 breast development.  
 
Any amount of spotting should be considered menarche. If Tanner Staging of 
breasts is performed as part of study procedures, please refer to the Reproductive, 
Pregnancy and Pediatrics Safety Committee Safety Guidance for Children in 
Clinical Trial regarding Tanner staging.  
Women not of 
child bearing 
potential  Females are conside red women not of child bearing potential if  
 they have a congenital anomaly such as Mullerian agenesis  
 they are infertile due to surgical sterilization, or  
 they are post -menopausal.  
 
Examples of surgical sterilization include: hysterectomy, bilateral oophorectomy, 
or tubal ligation.  
Post-menopausal 
state The post -menopausal state should be defined as:  
1. A woman at any age at least 6 weeks post -surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by operative note; or  
2. A woman at least 40 years of age and up to 55 years old with an intact 
uterus, not on hormone therapy, who has had cessation of menses for at 
least 12 consecutive months without an alternative medical cause, AND  
with a follicle -stimulating hormone >40 mIU/mL; or  
3. A woman 55  or older not on hormone therapy, who has had at least 12 
months of spontaneous amenorrhea ; or 
4. A woman at least 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy  
 
* Women should not be taking medications during ame norrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
SERMs, or chemotherapy that could induce transient amenorrhea.  
Abbreviations: SERM = selective estrogen receptor modulators ; WOCBP = woman of child bearing potential . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 89 10.4.2.  Contraception Guidance   
10.4.2.1.  Females   
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same sex 
relationship, as part of their preferred and usual lifestyle  
Must…  Must not…  
 agree to either remain abstinent, or  
 stay in a same sex relationship without 
sexual relationships with males   use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation  
 declare abstinence just for the duration of 
a trial, or  
 use the withdrawal method  
 
 
 
WOCBP who  are NOT completely abstinent as their preferred and usual lifestyle, or in a same sex 
relationship, as part of their preferred and usual lifestyle  
Topic  Condition  
Pregnancy testing  Negative  serum  result at screening , followed by a 
negative urine  result within 24 hours prior to 
treatment exposure.  
Contraception  Agree to use 2 forms of effective contraception, 
where at least one form must be highly effective 
(less than 1% failure rate)  for the duration of the 
trial and for 30 days thereafter.  
 
 
Examples of different forms of contraception:  
Methods  Examples  
Highly effective contraception   combination oral contraceptive pill and 
mini-pill 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 
pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopian tube implants (if confirmed by 
hysterosalpingogram)  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with sperm icide or cervical 
sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 90 o  diaphragm with spermicide, or  
o female condom with spermicide  
 
Note: The barrier method must include use of a 
spermicide ( that is , condom with spermicide, 
diaphragm with spermicide, female condom with 
spermicide) to be considered effective.  
Ineffective forms of contraception   spermicide alone  
 immunocontraceptives  
 periodic abstinence  
 fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, symptothermal)  
 withdrawal  
 post coital douche  
 lactational amenorrhea  
 
10.4.2.2.  Males   
The table below describes contraception guidance for all men.  
Topic  Guidance  
For all men  should refrain from sperm donation for the 
duration of the study and for 120 days (4 months)  
from the last dose of study intervention received  
Contraception for men with partners of 
childbearing potential    either remain abstinent (if this is their 
preferred and usual lifestyle), or  
 must use condoms during intercourse for 
the duration of the study, and 
 for 120 days (4 months)  from the last 
dose of study intervention received  
Contraception for men in exclusively same sex 
relationships, as their  preferred and usual lifestyle  Are not required to use contraception  
Examples  of highly effective, effective and unacceptable methods of contraception are listed in Section 
10.4.2.1 , Appendix 4. 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 91 10.5. Appendix  5: Genetics   
Use/Analysis of DNA  
Genetic variation may impact a participant’s response to study intervention, susceptibility to, and 
severity and progression of disease. Variable response to study intervention may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and excretion; 
mechanism of action of the drug ; disease etiology; and/or molecular subtype of the disease being 
treated. Therefore, where local regulations and IRB/IEC allow, a  blood sample will be collected 
for DNA analysis from consenting participants.  
DNA samples will be used for research related t o tirzepatide, OSA, obesity  and related diseases. 
They may also be used to develop tests/assays including diagnostic tests related to tirzepatide, 
OSA, and obesity . Genetic research may consist of the analysis of 1 or more candidate genes or 
the analysis of genetic markers throughout the genome or analysis of the entire genome (as 
appropriate).  
The samples may be analyzed as part of a multi -study assessment of genetic factors involved in 
the response to tirzepatide  or study interventions of this class to u nderstand study disease or 
related conditions.  
The results of genetic analyses may be reported in the CSR or in a separate study summary.  
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confidentiality.  
The samples will be retained while research on tirzepatide, OSA, and obesity  continues but no 
longer than the sample retention limits described in Section 10.1.12 , Appendix 1. 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 92 10.6. Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
10.6.1.  Hepatic Evaluation Testing   
See Sections  10.6.2  and 10.6.3 , Appendix 6  for guidance on appropriate test selection.  
The Lilly -designated central laboratory must complete the analysis of all selected testing except 
for microbiology testing.  
Local te sting may be performed in addition to central testing  when necessary for immediate 
participant management.  
Results  will be reported if a validated test or calculation is available.  
Hematology  Clinical Chemistry  
Hemoglobin  Total bilirubin  
Hematocrit  Direct bilirubin  
Erythrocytes (RBCs – red blood cells)  Alkaline phosphatase (ALP)  
Leukocytes (WBCs – white blood cells)  Alanine aminotransferase (ALT)  
Differential:  Aspartate aminotransferase (AST)  
  Neutrophils, segmented  Gamma -glutamyl transferase (GGT)  
  Lymphocytes  Creatine kinase (CK)  
  Monocytes  Other Chemistry  
  Basophils  Acetaminophen  
  Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
Ethyl alcohol (EtOH)  (quantitative)  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin  A (IgA) (quantitative)  
 
Hepatitis A virus (HAV) testing:  Immunoglobulin G (IgG) (quantitative)  
  HAV total antibody  Immunoglobulin M (IgM) (quantitative)  
  HAV IgM antibody  Phosphatidylethanol (P eth) 
Hepatis B virus (HBV) testing:  Urine Chemistry  
  Hepatitis B surface antigen (H bsAg)  Drug screen  
  Hepatitis B surface antibody (anti -HBs)  Ethyl glucuronide (EtG)  
  Hepatitis B core total antibody (anti -HBc)  Other Serology  
  Hepatitis B core IgM antibody  Anti-nuclear antibody (ANA)  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 93   Hepatitis B core IgG antibody  Anti-smooth muscle antibody (ASMA) a 
  HBV DNA b Anti-actin antibody c 
Hepatis C virus (HCV) testing:  Epstein -Barr virus (EBV) testing:  
  HCV antibody    EBV antibody  
  HCV RNA b   EBV DNA b 
Hepatitis D virus (HDV) testing:  Cytomegalovirus (CMV) testing:  
  HDV antibody    CMV antibody  
Hepatitis E virus (HEV) testing:    CMV DNA b 
  HEV IgG antibody  Herpes simplex virus (HSV) testing:  
  HEV IgM antibody    HSV (Type 1 and 2) antibody  
  HEV RNA b   HSV (Type 1 and 2) DNA  b 
Microbiology d Liver kidney microsomal type 1 (LKM -1) antibody  
Culture:   
  Blood   
  Urine   
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti -smooth muscle antibody (ASMA) is tested.  
d Assayed ONLY by investigator -designated local laboratory; no cent ral testing available.  
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 94 10.6.2.  Close Hepatic Monitoring   
Laboratory tests ( Section  10.2, Appendix 2), including ALT, AST, ALP, TBL, direct bilirubin, 
gamma -glutamyl transferase , and creatine kinase , should be repeated within 48 to 72 hours to 
confirm the abnormality and to determine if it is increasing or decreasing, if one or more of these 
conditions occur:  
If a participant with baseline results 
of…  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participant s with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participant s with 
Gilbert’s syndrome)  
Abbreviations: ALP = alkaline phosphatase ; ALT = alanine aminotransferase;  AST = aspartate aminotransferase; 
TBL = total bilirubin  level ; ULN = upper limit of normal . 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by the investigator in consultation with 
the Lilly -designated medical monitor. At a minimum, this evalu ation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical cond ition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results st abilize. Monitoring of ALT, AST, ALP, and  total 
bilirubin level  should continue until levels normalize or return to approximate baseline levels.  
10.6.3.  Comprehensive Hepatic Evaluation   
A comprehensive  evaluation should be performed to search for po ssible causes of liver injury if 
one or more of these conditions occur:  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 95 If a participant with baseline results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms a, or 
ALT or AST ≥5x ULN  
ALP <1.5x  ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participant s with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptoms a, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participant s with Gilbert’s syndrome)  
Abbreviations: ALP = alkaline phosphatase; ALT= alanine aminotransaminase; AST = aspartate aminotransferase; 
TBL = total bilirubin level; ULN = upper limit of normal . 
a Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/or eosinophilia >5%.  
At a minimum , this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for PT -INR; tests for viral hepatitis A, B, C, or E; tests 
for autoimmune hepatitis; and an abdominal imaging study (for example, ultrasound or CT scan).  
Based on the participant ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated medical monitor, including tests for hepatitis D virus , 
cytomegalovirus , Epstein -Barr virus , acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson’s disease, blood alcohol levels, uri nary ethyl glucuronide, and 
blood phosphatidylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist  consultation, magnetic resonance cholangiopancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data collection in hepatic safety CRF s should be performed  in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if b aseline 
ALT <1.5x ULN)  
 In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline on 2 
or more consecutive tests  
2. Elevated TBL to ≥ 2x ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert ’s syndrome)  
 In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
 In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline on 2 
or more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
5. Discontinuation of study intervention  due to a hepatic event  
Note : the interval between the 2 consecutive blood tests should be at least 2 days.   
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 96 10.7. Appendix 7: Medical Device Adverse Events (AEs),  Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies : Definition and Procedures for Recording, Evaluating, 
Follow -up, and Reporting   
Refer  to Appendix 3 for defin itions and procedures for recording, evaluating, follow -up, and 
reporting of all events.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 97 10.8. Appendix 8: Protocol GP IF Standardized Protocols for the 
Measurement of Height, Weight, Neck Circumference, Waist 
Circumference, Vital Signs, and Electrocardiogram   
The following information has been adapted from standardized physical measurement protocols 
for the World Health Organization’s STEPwise approach to Surveil lance (STEPS) (WHO 2017). 
10.8.1.  Measuring Height   
Step 1.  Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious  reasons can remain, but this s hould be worn by the participant at every clinic visit when 
their height is measured).  
Step 2.  Ask the participant to stand on the calibrated height measuring board (stadiometer) or 
against  a wall with their feet together and their knees straight with thei r heels against the 
backboard,  the stadiometer, or the wall.  
Step 3.  Ask the participant to look straight ahead without tilting their head up.  
Step 4.  Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in centimeters  to 1 decimal place.  
 
10.8.2.  Measuring Weight   
 Body weight measurements should be done in a consistent manner using a calibrated 
electronic scale capable of measuring weight i n kilograms to 1 decimal place.  
 All weights for a given participant should be measured using the same scale, 
whenever possible, at approximately the same time in the morning after evacuation of 
bladder contents . 
 Body weight will be measured in fasting state at all visits except Visit 1 . If the 
participant is not fasting, the participant should be called in for a new visit within the 
visit window to have the fasting body weight measured.  
Step 1.   Ask the participant to empty their pockets, remove their f ootwear, outerwear (coat, 
jacket, etc.), and any headgear (light headgear worn for religious reasons can remain, but this 
should be worn by the participant at every clinic visit when weight is measured).  
Step 2.   Make  sure the scale is placed on a firm, fl at, even surface (not on carpet, on a sloping 
surface, or a rough, uneven surface).  
Step 3.   Ask the participant to step onto the scale with 1 foot on each side of the scale.  
Step 4.   Ask the participant to stand still with arms by sides and then record we ight in kilograms 
to the nearest one -tenth kilogram . 
10.8.3.  Mea suring Hip and Waist Circumference   
 Hip circumference measurements should be obtained with the participant  in the standing 
position . The hip circumference  should be measured  at the maximal circumference of the 
buttocks.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 98  Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin of the last palpable rib and the top of the iliac c rest. 
 Measurements should be taken at the end of a normal expiration using a nonstretchable 
measuring tape. The tape should lie flat against the skin without compressing the soft 
tissue.  
 The waist circumference should be measured twice, rounded to the near est 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements will 
be recorded in the CRF. If the difference between the 2 measurements exceeds 1 cm, this 
set of measurements should be discarded and the 2 measurements repea ted. 
Step 1.  Ask the participant to wear light clothing (if available, patient gowns could also be used).  
Step 2.  Ask the participant to stand with their feet close together, arms at their side, body weight 
evenly distributed.  
Step 3.  Ask the participant t o relax and measure the participant’s waist circumference.  
10.8.4.  Measuring Neck Circumfer ence   
 
 Participants should look straight ahead  during the measurement , with shoulders  down 
(not hunche d). 
 Measure the neck circumference at a point just below the larynx (Adam’s Apple) and 
perpendicular to the long axis of the neck.  
 Do not place the tape measure over the Adam’s Apple.  
 The tape will be as close to horizontal as anatomically  feasible (the tape line in the 
front of the neck should be at the same height as the tape line in the back of the neck).  
 Care should be taken so as not to involve the shoulder/neck muscles (trapezius) in the 
measurement.  
 Round neck measurement up to the n earest half centimeter . 
10.8.5.  Vital Sign Measurements ( Blood Pressure and Heart Rate)  
 Vital sign measurements ( BP and heart rate, measured by pulse) should be taken before 
obtaining an ECG tracing and before collection of blood samples for laboratory testing  
 The participant should sit quietly for at least 5 minutes before vital signs measurements are 
taken  
 For each p arameter, 3 measurements will be taken using the same arm, preferably the 
nondominant arm  
 The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse 
and BP needs to be recorded in the CRF  
 Blood pressure must be taken with an automated BP instrument  
 If BP and pulse measurements are taken separately, pulse should be taken prior to BP. 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 99 Note:  In the event pulse measurement cannot be taken via an automated BP instrument , the 
preferred location for measurement of pulse is the radial  artery.  
10.8.6.  Electrocardiogram   
 All digital ECGs will be obtained using local  ECG machines.  
 12-lead ECGs should be obtained after the participant  has rested in a supine position for a t 
least 5 minutes.  
 Electrocardiograms should be collected prior to collection of blood samples for laboratory 
testing, including PK samples.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 100 10.9. Appendix 9: Provisions for Changes in Study Conduct Due to the 
COVID -19 Pandemic   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator.  
Study disruptions  due to the COVID -19 pandemic  
Individual, site, or regional restrictions due to the COVID -19 pandemic may cause disruptions to 
the conduct of the study. These disruptions may limit the abil ity of the investigators or 
participants, or both, to attend on -site visits or to conduct planned study procedures.  
Implementing changes due to  the COVID -19 pandemic  
After receiving the sponsor’s written approval, sites may implement changes if permitted b y 
local regulations.  
After approval by local ERBs/IRBs , regulatory bodies and any other relevant local authorities, 
implementation of these changes will not typically require additional notification to these groups, 
unless they have specific requirements in which notification is required (for example, upon 
implementation and suspension of changes). All approvals and notifications must be retained in 
the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will als o provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP , enabling 
participants to continue safely in the study and maintaining the integrity of the study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for:  
 participation in remote visits, as defined in Section “Remot e Visits”  
 dispensation of additional study intervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to implementation of 
these ac tivities.  
Changes in study conduct due to  the COVID -19 pandemic  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered pro tocol deviations.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 101 Remote visits  
Types of remote visits  
Telephone /Telemedicine  
Telephone or technology -assisted virtual visits, or both, are acceptable to complete appropriate 
assessments. Assessments to be completed in this manner include, but are not limited to, 
collection of AEs and PCs, concomitant medications  review , review stud y participant diary 
(including study intervention  compliance), review diet and exercise goals, C -SSRS (Since Last 
Visit Assessed) and PHQ -9. PROs will be completed by the participant on the provisioned 
device per the SoA. 
Mobile  healthcare  visit 
Healthcare  visits may be performed by a mobile healthcare provider at locations other than the 
study site when participants cannot travel to the site due to the COVID pandemic , if written 
approval is provided  by the sponsor . Procedures performed at such visits include, but are not 
limited to, weight measurement, blood sample  collection , vital signs ( temperature , PR, BP), 
concomitant medication review , conducting physical assessments, collection of AEs and PCs, 
and collecting health information. PROs will be comp leted by the participant on the provisioned 
device per the SoA. 
Every effort should be made for the participant to return to on -site visits as soon as reasonably 
possible, while ensuring the safety of the participant and investigational site staff.  
Data ca pture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon a s 
reasonably possible, while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory testing. However, central 
laboratory testing must be retai ned for  PK, immunogenicity, hsCRP, insulin and lipid samples . 
The local laboratory must be qualified in accordance with applicable local regulations.  
Study intervention and supplies  
When a  participant is unable to go to the site to receive study supplies d uring normal on -site 
visits, the site should work with the sponsor to determine appropriate actions. These actions may 
include:  
 asking the participant to go to the site and receive study supplies from site staff 
without completion of a full study visit  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 102  asking the participant’s designee to go to the site and receive study supplies on a 
participant’s behalf, and 
 arranging delivery of study supplies . 
These requirements must be met before action is taken:  
 Alternate delivery of study intervention should be perfo rmed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged, including 
verification of participant’s receipt of study supplies.  
 When delivering s upplies to a location other than the study site (for example, 
participant’s home), the investigator, sponsor, or both should ensure oversight of the 
shipping process to ensure accountability and product quality (that is, storage 
conditions maintained and i ntact packaging upon receipt).  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Screening period guidance  
To ensure safety of study participants, laboratory values and other eligibility assessments taken 
at Visit 1  are valid for a maximum of 90 days. The following rules will be applied for active  
participants not randomly assigned to study intervention  whose p articipation in the study must be 
paused due to the COVID -19 pandemic : 
 If screening is paused for less than 90 days from Visit 1  to Visit 2 : the participant will 
proceed to the next study visit per the usual SoA, provided that Visit 2  must be 
conducted within 90 days from Visit 1.  
o The site should conduct the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm th e impacted 
participant’s consent and document this confirmation in the source 
documentation.  
 If screening is paused for more than 90 days from Visit 1  to Visit 2 : the participant 
must be discontinued because of screening interruption due to the COVID -19 
pandemic . This is documented as a screen failure in the CRF. The participant can 
reconsent and be rescreened as a new participant. This rescreen is in addition to the 
one allowed by the main protocol.  The screening procedures per the usual SoA should 
be foll owed, starting at Visit 1  to ensure participant eligibility by Visit 2 . 
 
Adjustments to visit windows  
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual SoA. To maximize the possibili ty that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 103 This table describes the allowed adjustmen ts to visit windows.  
Visit Number  Tolerance  
Visit 1  
(Screening)  No change  
Visit 2 
(Randomization)  Within 90 days after Visit 1.  
Visits 3 through 6 Within 7 days before or after the intended date.  
Visits 7 through 
10 Within 14 days before or after the intended date.  
Visit 11  Within 14 days before the intended date, or up to 28 days 
after the intended date.  
Visit 801  Up to  28 days  after the intended date   
 
For participants whose visits have extended windows, additional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study.  
Documentation  
Changes to study conduct will be documented  
Sites will identify and doc ument the details of how participants, visits types, and conducted 
activities were affected due to the COVID -19 pandemic . Dispensing/shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents at alternate locations  
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 104 10.10.  Appendix 10: Abbreviations  and Definitions   
Term  Definition  
AASM  American Academy of Sleep Medicine  
Abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
ADA  antidrug antibody  
AE adverse event  
AHI Apnea -Hypopnea Index  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ANCOVA  analysis of covariance  
Apnea  decrease in airflow ≥90% from baseline for ≥10 seconds  
AST aspartate aminotransferase  
AX6 Axivity 6  
blinding/masking  A single -blind study is one in which the investigator and/or the investigator’s staff are 
aware of the treatment but the  participant  is not, or vice versa, or when the sponsor is 
aware of the treatment but the investigator and/ the investigator’s  staff and the 
participant  are not.  
A double -blind study is one in which neither the participant  nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participant s are aware of the treatment received.  
BMI body mass index  
BP blood pressure  
CBD  cannabidiol  
COA  clinical outcome assessment  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form; a  printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial participant . 
CSR  clinical study report  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CV cardiovascular  
Device deficiencies  Equivalent to product complaint  
DMC  data monitoring committee . A data monitoring committee, or data monitoring board 
(DMB)  is a group of independent scientists who are appointed to monitor the safety and 
scientific integrity of a human  research intervention, and to make recommendations to 
the sponsor regarding the stopping of a study for efficacy, or for harms, or for futility. 
The composition of the committee is dependent upon the scientific skills and 
knowledge required for monitoring  the particular study.  
DPP-4 dipeptidyl -peptidase -4 
EAS efficacy analysis set  
ECG  electrocardiogram  
ED early discontinuation  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
enroll  The act of assigning a participant  to a treatment. Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 105 enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
ERB  ethical review board  
EQ-5D-5L EuroQol - 5 Dimension - 5 Level  
ESS Epworth Sleepiness Scale  
FAS full analysis set  
FG fasting glucose  
FOSQ  Functional Outcomes of Sleep Questionnaire  
GCP  good clinical practice  
GI gastrointestinal  
GIP glucose -dependent insulinotropic polypeptide  
GLP-1 glucagon -like peptide -1 
GLP-1R glucagon -like peptide -1 receptor  
GLP-1RA glucagon like peptide 1 receptor  
HbA1c  hemoglobin A1c  
HDL high-density lipoprotein  
HSAT  home sleep apnea test  
hsCRP  high-sensitivity C -reactive protein  
Hypopnea  an abnormal respiratory event lasting ≥10 seconds with ≥30% reduction in 
thoracoabdominal movement or airflow as compared to baseline, and with ≥ 4% oxygen 
desaturation.  
IB Investigator’s Brochure  
ICF informed  consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committees  
IMP Investigational Medicinal Product  (see also “ investigational product ”) 
A medicinal product which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
informed consent  A process by which a participant  voluntarily confirms their willingness to participate in 
a particular study, after having bee n informed of all aspects of the study that are 
relevant to the participant’s  decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent form . 
INR International normalized ratio  
interim analysis  An in terim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested o r used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB institutional review board  
ISA intervention -specific appendi x 
ISR injection site reaction  
ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant  (that is, the 
planned treatment regimen) rather than the actual treatment given. It  has the 
consequence that participant  allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.  
IWRS  interactive web -response system  
MACE  major adverse cardiovascular events  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 106 medication error  Errors in the prescribing, dispensing, or administration of a study intervention, 
regardless of whether or not the medication is administered to the participant or the 
error leads to an AE. Medication erro r generally involve a failure to uphold one or more 
of the five “rights” of medication use: the right participant, the right drug, the right 
dose, right route, at the right time.  
In addition to the core five rights, the following may also represent medicat ion errors:  
• dose omission associated with an AE or a product complaint  
• dispensing or use of expired medication  
• use of medication past the recommended in -use date  
• dispensing or use of an improperly stored medication  
• use of an adulterated dosage form or administration technique inconsistent with the 
medication's labeling (for example, Summary of Product Characteristics, IB, local 
label, protocol), or  
• shared use of cartridges, prefilled pens, or both.  
MEN  multiple endocrine neoplasia  
MI myocard ial infarction  
misuse  Use of a study intervention for self -treatment that either is inconsistent with the 
prescribed dosing regimen, indication, or both, or is obtained without a prescription . 
MMRM  Mixed model repeated measures  
MTC  medullary thyroid cancer  
MTD  maxim um tolerated dose  
OGTT  oral glucose tolerance test  
OSA  obstructive sleep apnea  
OTC  Over the counter  
PAP positive airway pressure  
participant  Equivalent to  CDISC term  “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control . 
PC product complaint  
PGIC  Patient Global Impression of Change  
PGIS  Patient Global Impression of Status  
PHQ -9 Patient Health Questionnaire -9 
PK/PD  pharmacokinetics/pharmacodynamics  
PR pulse rate  
PRO/ePRO  patient -reported outcomes/electronic patient -reported outcomes  
PROMIS  Patient -Reported Outcomes Measurement Information System  
PSG  polysomnography  
QTc corrected QT interval  
QW weekly  
SAE serious adverse event  
SAP statistical analysis plan  
SASHB  sleep apnea specific hypoxic burden  
SBP systolic blood pressure  
SC subcutaneous  
SD standard deviation  
screen  The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SF-36v2  Short -Form 36 version 2  
SIB suicidal ideation and behavior  
SoA Schedule of Activities  
SS safety analysis set  
T1DM  Type 1 diabetes mellites  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 107 T2DM  Type 2 diabetes mellites  
TBL total bilirubin  level  
TEE total energy expenditure  
TEAE  treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
THC Tetrahydrocannabinol  
TSH thyroid -stimulating hormone  
UACR  urinary albumin/creatinine ratio  
ULN upper limit of normal  
WOCBP  woman of childbearing potential  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 108 10.11.  Appendix 11: Country -Specific Requirements   
10.11.1.  Germany   
This section describes protocol changes applicable for adult participants in study sites in 
Germany.  
This table describes the changes and provides a rationale for the changes.  
Protocol Section Number and 
Name  Description of the 
Change  Brief Rationale  
7.2. Participant Discontinuation/ 
Withdrawal  from the Study  
8.3. Adverse Events, Serious 
Adverse Events, and Product 
Complaints  
10.1.3  Informed Consent Process  
10.10. Abbreviations and 
Definitions  Deleted references to 
“legally authorized 
representative,” “legal 
guardian,” “parents”  The German Drug Law (Arzneimittelgesetz – 
AMG) requires per Paragraph 40 (1 -3) and 
Paragraph 41 (3) that adult participants act 
on their own behalf and provide their own 
written informed consent. If written consent 
is not possible, verbal consent with a witness 
is acceptable. No legal representative consent 
is accepted.  
The revised text in the following subsections show the changes applicable  for adult p articipants  
to study sites in Germany. Additions are identified by underline . Deletions are identified by 
strikethrough format . 
7.2. Participant Discontinuation/Withdraw al from the Study  
Discontinuation  is expected to be uncommon.  
A participant may withdraw from the study:  
 at any time at the participant’s own request  
 at the request of the participant’s designee (for example, parents or legal guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or administrative 
reasons  
o If the participant becomes pregnant during the study (see Section 8.3.2  for 
additional details)  
 if enrolled in any other clinical study involving an i nvestigational product, or enrolled in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study  
 if the participant, for any reason, requires treatment with a therapeutic agent that is 
prohibited by the prot ocol and has been demonstrated to be effective for treatment of the 
study indication. In this case, discontinuation from the study occurs prior to introduction 
of the new agent.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 109 8.3. Adverse Events, Serious Adverse Events, and Product Complaints  
The defi nitions of the following events can be found in Section 10.3, Appendix 3:  
 AEs 
 SAEs  
 PCs 
These events will be reported by the participant (or, when appropriate, by a caregiver,  or 
surrogate , or the participant's legally authorized representative) . 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 110 10.1.3 Informed Consent Process  
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benef its, to the participant or the participant’s legally authorized 
representative and answer all questions regarding the study.  
Participants must be informed that their participation is voluntary. Participants or their legally 
authorized representatives will be required to sign a statement of informed consent that meets the 
requirements of 21 C ode of Federal Regulations  50, local regulations, ICH guidelines, privacy 
and data protection requirements, where applicable, and the IRB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant was entered in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized 
representative and is kept on file.  
Partici pants who are rescreened are required to sign a new ICF.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 111  
10.10. Appendix 10: Abbreviations and Definitions  
 
enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives . 
 
 
 
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 112 10.12.  Appendix 12: Protocol Amendment History   
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment [b]: 30-Sep-2022  
This amendment is considered to be substantial.  
 
The amendment is considered to be substantial because it is likely to have a significant impact on 
the  
● safety or the rights of the study participants,  and 
● reliability and robu stness of the data generated in the clinical study . 
Overall Rationale for the Amendment:  
This amendment includes the addition of a key secondary objective, “Change in AHI”. The 
endpoint for key secondary objective “Change in SBP” and other secondary object ive “Change 
in DBP” has been updated to Week 48 from Week 52. Changes have been made to the Schedule 
of Activities to reflect the synchronization of timing of C -SSRS to PHQ -9. 
 
Protocol changes have been made as outlined in the following table.  
 
Section # and Name  Description of Change  Brief Rationale  
1.1. Synopsis  
and  
3. Objectives, Endpoints, and 
Estimands  
 Key Secondary Objectives: 
Added “Change  in AHI ” as a 
key secondary objective with 
endpoint “Change in AHI”  To align with 
recommendations from 
health authority.  
Key Secondary Objectives:  
Moved “change in SBP” to 
“From baseline to Week 48” 
section  BP will be assessed at Week 
48 because PAP suspension 
at Week 52 may confound 
BP assessment.  
Added footnote a  
“BP will be assessed at Week 48 
because PAP suspension  at 
Week 52 may confound BP 
assessment ”. For additional information.  
1.3. Schedule of Activities  
 Removed text, “Note: Visit 10 is 
eligible to be conducted 
remotely (that is, by telephone, 
IT-assisted virtual visit, or in 
combination with on -site visit) 
at the direction of the sponsor, 
according to local laws and 
regulations.”  Vital signs will be measured 
at Week 48, so this visit will 
be on site.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 113 Section # and Name  Description of Change  Brief Rationale  
 “Fasting Visit” row: Removed 
text, “If V10 is remote, then the 
visit will not be fasting.”  This instruction is no longer 
applicable.  
“Weight” row: Removed text, 
“If V10 is remote, then weight 
will not be obtained at the visit.”  This instruction is no longer 
applicable.  
“Vital signs” row: Removed 
text, “If  V10 is remote, vital 
signs will not be obtained at the 
visit.”  This instruction is no longer 
applicable.  
“Symptom -directed physical 
assessment” row: Removed text, 
“If V10 is remote, then 
symptom -directed physical 
assessment will not be done at 
the visit .” This instruction is no longer 
applicable.  
Removed “Schedule Sleep 
Center Study for PSG” and 
“Sleep Center Study for PSG” 
from ED visit.  Sleep study is not required 
for participants who 
discontinue early.  
“Review Lifestyle Program 
instructions” row : Updated 
comment to “Diet and exercise 
goals established during the 
lifestyle consultation and the 
importance of adherence to the 
lifestyle component of the trial 
will be reinforced at each trial 
contact by study staff.”  To clarify the requirement.  
“ESS , EQ-5D-5L, FOSQ, and 
PGIS” rows: Updated comment 
“When the PROs are scheduled 
for visits at which the PSG will 
be done, they should be 
completed on the same day as 
PSG and in the following order 
(FOSQ, ESS, PROMIS Short 
Form v1.0 Sleep Disturbance 8b, 
PROMIS Short Form v1.0 
Sleep -related Impairment 8a, 
PGIS, PGIC, SF -36v2 acute 
form, and EQ -5D-5L) before the To clarify the requirement.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 114 Section # and Name  Description of Change  Brief Rationale  
PSG is conducted, and should be 
done at the same time of day for 
each of those visits . Completing 
the PRO assessments on the next 
day after PSG is not considered 
a protocol violation.  
 “PHQ -9”, “C -SSRS 
screening/baseline”, and “C -
SSRS (since last visit version)” 
rows: added “if both collected  
on the same day” to comments.  To clarify timing and allow 
further flexibility for AE 
collection independent of 
PHQ -9 and C -SSRS 
assessments . 
“C-SSRS (since last visit 
version)” row:  
Removed assessment from 
Visits 3, 4, 5, 6, 8, 9, 10, and 
801. Collectio n schedule has been 
updated to align with PHQ -9 
assessments.  
“Participant returns all unused 
study intervention” row: 
Removed text, “If V10 is 
remote, participant will return 
any unused study intervention 
dispensed at V9 during the V11 
visit.”  This instruction is no longer 
applicable.  
“Assess study intervention 
compliance” row: Removed text, 
“If V10 is remote, the next study 
intervention compliance will be 
done at V11.”  This instruction is no longer 
applicable.  
3. Objectives, Endpoints, and 
Estima nds Other Secondary Objectives:  
Moved “change in DBP” to 
“From baseline to Week 48” 
section  BP will be assessed at Week 
48 because PAP suspension 
at Week 52 may confound 
BP assessment.  
5.2. Exclusion Criteria  Exclusion Criterion 42: Updated 
formatting.  For clarification.  
Exclusion Criterion 53: 
Removed “(4 months for studies 
conducted in Japan, 3 months 
for studies conducted in the 
United Kingdom).  This information is no 
longer applicable.  
6.5. Dose Modification  Modified text, “ Dose 
modification is permitted for Clarification.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 115 Section # and Name  Description of Change  Brief Rationale  
 management of intolerable GI 
symptoms during the first 24 
weeks of the treatment period  
(Section 6.5.1).  
Modified text, “ Participants who 
do not tolerate at least 10 mg 
even after the described 
measures, including  1 de-
escalation and re -escalation 
attempt, will be discontinued 
from the study intervention but 
remain in the study for 
continued follow -up.” Clarification.  
6.5.1. Management of 
Participants with 
Gastrointestinal Symptoms  
 Modified text, “ For participants 
unable to tolerate any dose  
escalation  between 7.5 mg and 
15 mg inclusive, despite the 
above measures, the investigator 
should contact Lilly to consider  
a dose de -escalation step with 
subsequent re -escalation by 2.5 
mg every 4 weeks up to MTD 
will be allowed  in a blinded 
fashion, to reach either the 10 -
mg or 15 -mg dose as described 
below .” Direct the investigator to 
contact sponsor to ensure 
that dose modifications are 
completed according to 
protocol.  
Added text “ Dose modifications 
after the first 24 weeks of the 
treatment period are not 
permitted. For temporary study 
treatment discontinuation see 
Section 7.1.2. ” Clarification.  
6.5.1. Management of 
Participants with 
Gastrointestinal Symptoms  Modified text,  
“Participants who tolerate  
• 10 mg, but do not 
tolerate 12.5 mg or 15 mg even 
following the above measures, 
including 1 de-escalation and re -
escalation attempt, will continue 
on 10 mg as their MTD dose.  Clarification.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 116 Section # and Name  Description of Change  Brief Rationale  
• 12.5 mg, but do not 
tolerate 15 mg even after the 
above measures, including  1 de-
escalation and re -escalation 
attempt, will continue on 10 mg 
as their MTD dose. ” 
7.1. Discontinuation of Study 
Intervention  Removed text in clinical 
considerations section, 
“inadvertent enrollment if 
continued treatment with study 
interven tion would not be 
medically appropriate”   
Participants who do not meet 
enrollment criteria will 
discontinue from the study.  
Added text, “ The participant 
should be referred to a MHP for 
further evaluation and care. ” To provide further detail for 
participant care.  
7.2. Participant 
Discontinuation/Withdrawal 
from the Study  Added text, “A participant will 
be withdrawn from the study in 
case of inadvertent enrollment”  Text updated to align with 
relevant edits in Section 7.1.  
8.2.3. Electrocardiogram s 
(ECG)  Modified instructions for timing 
of ECG collection.  
“ECGs should be collected at 
least 30 minutes  prior to 
collection of blood samples for 
laboratory testing, including PK 
samples. Participants should be 
supine for at least  approximately  
5 to 10  minutes before ECG 
collections and remain supine 
but awake during the ECG 
collection. ECGs may be 
repeated at the investigator’s 
discretion at any visit. ” Clarification.  
8.3.1.1. Adverse Event 
Monitoring with a 
Systematic Questionnaire  Added text, “ if AE  and C -
SSRS/PHQ -9 collections done 
on the same day”.  To clarify timing and allow 
further flexibility for AE 
collection independent of 
PHQ -9 and C -SSRS 
assessments . 
9.2. Analyses Sets FAS and EAS descriptions 
updated to include “excluding 
those discontinui ng study due to 
inadvertent enrollment”  Text revised to reflect 
updated definitions for FAS 
and EAS . 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 117 Section # and Name  Description of Change  Brief Rationale  
Added “(last dose +7 days) ” to 
the description of data excluded 
due to the discontinuation of 
study intervention in the EAS 
population.  Clarification.  
9.3. Statistical Analysis  Modified text for “hybrid” 
estimand, changed “hybrid” to 
“treatment regimen” throughout 
Section 9.3.  To keep terminology 
consistent with the literature.  
9.3.1. General 
Considerations  Modified text, “Efficacy 
analyses will be cond ucted on 
all participants randomly 
assigned to study intervention 
according to the treatment to 
which the participants are 
assigned and were exposed to at 
least one dose.  To add details for 
clarification.  
Modified text, “For the 
“efficacy” estimand, the analysis 
will include data collected prior 
to permanent discontinuation of 
study intervention and will  be 
conducted using the EAS.  This was duplicate 
information.  
“Missing Value Imputation” 
information mov ed and 
modified.  To reflect that the endpoint 
for SBP is at Week 48 
instead of Week 52 and to 
clarify that no explicit 
imputation will be 
performed for efficacy 
analysis relative to 
“efficacy” estimand.  
 Moved description of handling 
of missing data for “efficacy ” 
estimand earlier in the 
paragraph.  Clarification.  
9.3.2. Primary Analysis  
 Deleted text, “There will be 2 
primary analysis methods, each 
tested at the full significance 
level of 0.05”  This information has been 
moved to the last sentences 
of the primary analysis 
section and key secondary 
analysis section for 
clarification.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 118 Section # and Name  Description of Change  Brief Rationale  
Modified text, “Missing values 
will be imputed following 
imputation methods  based  on the 
strategy to handle intercurrent 
events  described in Section 
9.3.1”  Clarification.  
Added text, “Analysis aligned to 
each estimand will be evaluated 
at the full significance level of 
0.05.  To substitute the deleted text 
“There will be 2 primary 
analysis methods, each 
tested at the full significance 
level of 0.05”.  
9.3.3. Analysis of Key 
Secondary Endpoints  
 Updated text, “Analysis of 
change in AHI,  percent change 
from baseline in body weight, 
change in SBP, and  CRP at the 
52-week visit and change in 
SBP at the 48 -week visit  will be 
conducted in a manner similar to 
the primary efficacy ana lyses 
with baseline AHI stratum added 
in the model, and baseline of the 
corresponding variable as a 
covariate.  To align with changes in 
Section 3.  
Added text, “Analysis of change 
in AHI will not include the 
baseline AHI stratum.”  Clarification . 
Added text, “Analysis aligned to 
each estimand will be evaluated 
at the full significance level of 
0.05 contingent on reaching 
statistical significance of the 
primary objective.”  To substitute the deleted text 
“There will be 2 primary 
analysis methods, each 
tested at the full significance 
level of 0.05” . 
10.3.7.1. Hypoglycemia  Updated text, “Hypoglycemic 
episodes will be recorded in the 
eDiary  on a specific CRF  and 
should not be recorded as AEs 
unless the event meets serious 
criteria.  Correction.  
10.3.7.3. Injection -Site 
Reactions  Modified text, “ At the time of 
AE occurrence in the tirzepatide 
group , samples will be collected Correction.  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 119 Section # and Name  Description of Change  Brief Rationale  
for measurement of tirzepatide 
ADAs and tirzepatide 
concentration .” 
10.8.5. Vital Sign 
Measurements (Blood 
Pressure and H eart Rate)  Modified text, “  
 The participant should sit 
quietly for at least 5 minutes 
before vital signs 
measurements are taken ” Clarification.  
10.8.6. Electrocardiogram  Modified text, “  
 12-lead ECGs should be 
obtained after the participant  
has rested in a supine 
position for at least 5 10 
minutes.  
 Electrocardiograms should 
be collected at least 30 
minutes  prior to collection of 
blood samples for laboratory 
testing, including PK 
samples.  
 Electrocardiograms  should 
be obtained approximately 1 
minute apart, with all 3 
tracings to be obtained 
within approximately 5 
minutes. Measurements that 
deviate substantially from 
previous readings should be 
repeated immediately. ” Clarification. One tracing of 
ECG is consid ered adequate.  
Throughout  Editorial corrections.  Minor, therefore not 
described.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 120  
Amendment a: 10-Feb-2022  
 
Overall Rationale for the Amendment : 
This amendment corrects terminology used in the protocol for intervention -specific appendix 
(ISA), and add s selected clarifications.   
 
Section # and Name  Description of Change  Brief Rationale  
Title Page  
1.1. Synopsis  
1.3. Schedule of Activities  
10.10. Abbreviations and 
Definitions  Changed “indication -specific 
appendix” to “intervention -
specific appendix.  Correction.  
1.3. Schedule of Activities  “Symptom -directed physical 
assessment” row: Clarified 
marks for symptom -directed 
physical assessment during the 
study, and added a clarifying 
statement in notes.  Clarification.   
Original language could be 
interpret ed to mean symptom -
directed physical assessment 
is required at all visits. 
Symptom -directed physical 
assessment from visits 2 -11 
and ED will be conducted at 
the discretion of the PI, as 
indicated based on participant 
status and standard of care . 
 “Participant diary dispensed” 
row: Specified which diaries are 
electronic versus paper.  Clarification.  
 “Review Lifestyle Program 
instructions” row: comments 
updated/moved from the 
“Review diet and exercise goals” 
row, which has been deleted.  Clarificati on. 
 “Review diet and exercise goals” 
row: Removed.   Clarification. This review is 
part of Review Lifestyle 
Program instructions.  
5.2. Exclusion Criteria  Deleted criterion 48.  Duplicate criterion 
(Criterion  49). 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 121 Section # and Name  Description of Change  Brief Rationale  
8.1.3.1. Actigraphy  Modified text, “Participants 
should wear the aActigraphy 
device for 7 consecutive days, 5 
times during the study, per the 
SoA.”  Clarification.  
8.2.1. Physical 
Examination  Modified text, “ A symptom -
directed physical assessment  will 
be performed at visits  as 
indicated in the SoA, as 
clinically indicated. ” Clarification, for consistency 
with changes in the 
“Symptom -directed physical 
assessment” row in the SoA.  
10.8.2. Measuring Weight  Modified text, “Body weight will 
be measured in fasting state at all 
visits except Visit 1 .” Clarification.  
Throughout  Editorial corrections.   Minor, therefore not 
described.  
  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 122 11. References   
[ADA] American Diabetes Association Glycemic targets: St andards of medical care in diabetes - 
2020. Diabetes Care . 2020:43 (Suppl 1):S6 6–S76. https:// doi.org/10.2337/dc20 -S006  
[AHRQ] Agency for Healthcare Research and Quality. Continuous positive airway pressure 
treatment for obstructive sleep apnea. Accessed Jul y 20, 2021 . 
https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/drafts -for-review/sleep -
apnea -draftreport.pdf  
Alosh M, Bretz F, Mohammad H. Advanced multiplicity adjustment methods in clinical trials. 
Stat Med . 2014;33(4):693 -713. https:// doi.org/10.1002/sim.5974  
Banks PA, Freeman ML ; Practice Parameters Committee of the American College of 
Gastroenterology . Practice guidelines in acute pancreatitis. Am J Gastroenterol.  
2006;101(10):2379 -2400.   
Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0  mg in individuals with obesity 
and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical 
trial. Int J Obes  (Lond). 2016;40(8):1310 -1319 . 
Bretz F, Posch M, Glimm E, et al. Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests . Biom J.  2011; 53(6):894 -913. 
https:// doi.org/10.1002/bimj.201000239  
Currie AC, Kaur V, Carey I, et al. Obstructive sleep apnea remission following bariatric surgery: 
a nat ional registry cohort study . Surgery Obes Relat Dis . 2021;17(9):1576 -1582.  
https://doi.org/10.1016/j.soard.2021.05.021  
Dahl D, Onishi Y, Norwood P, et al. Tirzepatide, a dual GIP/GLP -1 receptor agonist, is effective 
and safe when added to basal insulin for  treatment of type 2 diabetes (SURPASS -5). Diabetes . 
2021;70(suppl_1). https://doi.org/10.2337/db21 -80-LB 
Danne T, Philotheou A, Goldman D, et al. A randomized trial comparing the rate of 
hypoglycemia – assessed using continuous glucose monitoring – in 125 preschool children 
with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study ). 
Pediatr Diabetes . 2013;14(8):593 -601. https://doi .org/10.1111/pedi.12051  
EuroQol Research Foundation. EQ -5D-5L user guide, version 3.0. Updated September 2019 . 
https://euroqol.org/publications/user -guides  
FAO/WHO/UNU. Human energy requirements. Report o f a joint FAO/WHO/UNU Expert 
Consultation.  Rome . 2004.  
[FDA] Food and Drug Administration. Guidance for Industry. Drug -Induced Liver Injury: 
Premarketing Clinical Evaluation . July 2009.  https://www.fda.gov/regulatory -
information/search -fda-guidance -documents/drug -induced -liver-injury -premarketing -clinical -
evaluation  
Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical 
trials . Stat Med.  1999;18(11):1341 -1354. https://doi.org/ 10.1002/(sici)1097 -
0258(19990615)18:11<1341::aid -sim129>3.0.co;2 -7 
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 123 Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients 
with type 2 diabetes. N Engl J Med . 2021;385(6):503 -515. 
https://doi. org/10.1056/nejmoa2107519  
Gottlieb DJ, Punjabi NM . Diagnosis and management of obstructive sleep apnea: a review . 
JAMA . 2020; 323(14):1389 -1400. https://doi.org/10.1001/jama.2020.3514  
Hamilton GS, Gupta R, Vizcarra D, et al; Guidelines Committee Members and Governing 
Council of the World Sleep Society. Endorsement of: “clinical practice guideline for 
diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medi cine 
clinical practice guideline” by the World Sleep Society. Sleep Med . 2021;79:152 -154. 
https://doi.org/10.1016/j.sleep.2020.12.044.  
Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of 
adult obstructive sleep apnea. A n Official American Thoracic Society Clinical Practice 
Guideline. Am J Respir Crit Care Med . 2018;198(6):e70 -e87. 
https://doi.org/10.1164/rccm.201807 -1326ST  
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. 
Sleep . 1991; 14(6):540 -545. https://doi.org/10.1093/sleep/14.6.540  
Koizumi M, Takada T, Kawarada Y, et al. JPN guidelines for the management of acute 
pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg. 
2006;13(1):25 -32. https://doi. org/10.1007/s00534 -005-1048 -2 
Kroenke K, Spitzer RL, Williams JB. The PHQ -9: validity of a brief depression severity 
measure. J Gen Intern Med . 2001;16(9):606 -613. 
[Lilly]. Eli Lilly and Company. Lilly ’s tirzepatide achieves all primary and key secondary study 
outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular 
risk in SURPASS -4 trial. Published May 20, 2021. Accessed July 15, 2021. 
http://lilly.mediaroom.com/2021 -05-20-Lillys -tirzepatide -achieves -all-primary -and-key-
secondary -study -outcomes -against -insulin -glargine -in-adults -with-type-2-diabetes -and-
increased -cardiovascular -risk-in-SURPASS -4-trial 
Ludvik B, Giorgino F, Jodar E, et al. Efficacy and safety of tirzepatide, a dual GIP/GLP -1 
receptor agonist, compared w ith insulin degludec in patients with type 2 diabetes (SURPASS 
3). Diabetes . 2021;70(suppl_1). https://doi.org/10.2337/db21 -78-LB 
Maruish ME, ed itor. User’s manual for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI: Quality  
Metri c Incorporated; 2011 . 
[Northwestern]. Northwestern University. PROMIS Short Form v1.0 – Sleep -Related 
Impairment 8a. Published May 09, 2016 a. Accessed Dec 01, 2021. 
https://www.healthmeasures.net/index.php?option=com_instruments&view=measure&id=185
&Itemid=992  
[Northwestern]. Northwestern University. PROMIS Short Form v1.0 – Sleep  Disturbance 8b . 
Published May 03, 2016 b. Accessed Dec 01, 2021. 
https://www.healthmeasures.net/index.php?option=com_instruments&view=measure&id=184
&Itemid=992  
Approved on 02 Jun 2023 GMT
CONFIDENTIAL   Master Protocol I8F -MC-GPIF( c) 
 124 Opperer M, Cozowicz C, Bugada D, et al. Does obstructive sleep apnea influence perioperative 
outcome? A qualitative systematic review for the society of anesthesia and sleep medicine task 
force on preoperative preparation of patients with sleep -disordered breathing . Anesth Analg . 
2016;122(5):1321 -1334. https://doi.org/10.1213/ane.0000000000001178  
Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of 
composite endpoints in clinical trials based on clinical priorities . Eur Heart J . 2012; 33(2):176 -
182. https://doi.org/10.1093/eurheartj/ her352 
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP -1 
receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS -1): a double -blind, 
randomised, phase 3 trial. Lancet . 2021;398(10295):143 -155. https://doi.org/10.1016/s0140 -
6736(21)01324 -6 
Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons Inc.; 
1987.  
The Columbia Lighthouse Project. The Columbia Protocol for Research. Columbia -Suicide  
Severity Rating Scale Scoring and Data Analysis Guide. Version 2.0. Published Feb 2013.  
Accessed August  03, 2021 . http://cssrs.columbia.edu/wp -
content/uploads/ScoringandDataAnalysisGuide -for-Clinical -Trials -1.pdf  
Tietjens JR, Claman D, Kezirian EJ, et al.  Obstructive sleep apnea in cardiovascular disease: a 
review of the literature and proposed multidisciplinary clinical management strategy . J Am 
Heart Assoc . 2019; 8(1):e010440. https://doi.org/10.1161/JAHA.118.010440  
Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the 
challenge to effective treatment . Proc Am Thorac Soc . 2008; 5(2):173 -178. 
https://doi.org/10.1513/pats.200708 -119MG 
Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes 
for disorders of excessive sleepiness. Sleep . 1997; 20(10):835 -843. 
Weaver T,  Menno D, Bron M, et al. Determination of thresholds for minimally important 
difference and clinically important response on the functional outcomes of sleep questionnaire 
short version in adults with narcolepsy or obstructive sleep apnea. Sleep Breath . 
2021;25(3):1701 -1715.  
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements 
overestimate the incidence of inpatient hypoglycemia and severe hyperglycemia.  J Diabetes 
Sci Technol.  2010;4(3):577 -582. https://doi.org/10.1177/193229681000400311  
[WMA] World M edical Association . World Medical Association  Declaration of Helsinki: ethical 
principles for medical research involving human subjects . JAMA . 2013; 310(20):2191 -2194. 
https://doi.org/10.1001/jama.2013.281053  
[WHO] World Health Organization. WHO STEPS surve illance manual: the WHO STEPwise 
approach to noncommunicable disease risk factor surveillance. Updated January 26, 2017. 
Accessed November 04, 2021. 
https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf  
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or 
both. N Engl J Med.  2017; 377(1):62 -70. https:// doi.org/10.1056/NEJMra1510062  
Approved on 02 Jun 2023 GMT
Signature Page for VV-CLIN-116270 v1.0
Signature Page for VV-CLIN-116270 v1.0Approval
Approval
Approved on 02 Jun 2023 GMT
PPD